Analiza porównawcza własności fizycznych miejsc wiązania antybiotyków aminoglikozydowych w RNA i białkach by Romanowska, Julia
University of Warsaw
Faculty of Physics
Julia Romanowska
Comparing physical properties of
aminoglycoside antibiotics’ binding
sites in RNA and proteins
PhD dissertation
Supervisor:
Joanna Trylska, PhD, Assoc. Prof.
Centre of New Technologies,
University of Warsaw
Warsaw
June 2012
Abstract
Aminoglycoside antibiotics have been in use for more than 60 years, helping combat severe
bacterial infections. Due to this long time of usage, more and more bacteria become resistant
to one or several drugs from this group. This spread of resistant species is alarming and
additionally, there is little knowledge about the mechanisms of bacterial resistance.
In order to broaden our understanding of how bacteria combat aminoglycosides, we
performed computer simulations of various molecules that bind aminoglycosides in a bac-
terial cell: (i) the primary binding site, called the A-site and located in ribosomal RNA,
wild type and with mutations that decrease the aminoglycoside binding affinity; and (ii) the
aminoglycoside modifying enzymes (AMEs), which are produced by bacteria to inactivate
these drugs. The mutations of the RNA A-site were chosen based on previous experimental
studies on whole bacteria. These studies showed that even single base substitutions were
sufficient to make bacteria resistant, but did not explain how this resistance was gained on
an atomic level. There are many AMEs and they vary a lot among themselves, yet they all
have a narrow specificity towards aminoglycosides, which are quite homogeneous group.
The two main questions we have posed in our research are: (i) what are the physical grounds
of bacteria becoming less susceptible to aminoglycosides due to RNA A-site mutations; and
(ii) how different AMEs attract aminoglycosides and interact with them?
We performed all-atom molecular dynamics (MD) simulations of the A-site model with
selected mutations and of AME representatives. In addition, the complexes of these biomol-
ecules with aminoglycosides were simulated. For comparison, we also performed simula-
tions of the wild type A-site model and of the aminoglycosides in water. We used various
biophysical methods to analyze these simulations and to study: internal dynamics of the
biomolecules; electrostatic potential, shape, and volume of the binding pockets; types of
interactions with aminoglycosides; and changes in conformations of aminoglycosides. In
addition, we developed and implemented an algorithm that helps describe molecular mo-
tions.
We found that different A-site mutations affect different features of the RNA binding
site. Some of them changed the mobility of the nucleic bases, and therefore the shape of the
A-site was altered. Other mutations changed the electrostatic potential inside the binding
site, thus making it almost unrecognizable to aminoglycosides. The study of AMEs showed
that apart from their structural and sequence-related diversity, they differ in the internal
movement patterns. However, these enzymes interact with aminoglycosides very similarly,
using mainly electrostatic interactions. Interestingly, we noticed that these interactions were
copied from the RNA:aminoglycoside complex. Our findings were in agreement with ex-
perimental studies and also helped to explain some of their outcomes. The results presented
in this dissertation may help design new antibiotics that would overcome the bacterial re-
sistance.
Dissertation title and summary in Polish
Analiza porównawcza własnos´ci fizycznych miejsc wia˛zania antybiotyków
aminoglikozydowych w RNA i białkach
Od ponad 60 lat antybiotyki aminoglikozydowe sa˛ z powodzeniem stosowane w szpi-
talach przeciwko cie˛z˙kim infekcjom bakteryjnym. Jednak pojawianie sie˛ coraz wie˛kszej
liczby przypadków bakterii opornych na stosowane aminoglikozydy sprawia, z˙e badania
mechanizmów opornos´ci u bakterii staja˛ kluczowe w dalszej skutecznej walce z infekcjami
tego typu.
Przeprowadziłam komputerowe symulacje biomolekuł, które oddziałuja˛ z antybioty-
kami aminoglikozydowymi we wne˛trzu komórek bakteryjnych. Badanymi obiektami sa˛:
(i) główne miejsce wia˛zania aminoglikozydów, zwane miejscem A, w rybosomalnym RNA;
natywne oraz z mutacjami powoduja˛cymi wzrost opornos´ci u bakterii; a takz˙e (ii) enzymy
modyfikuja˛ce aminoglikozydy (ang. aminoglycoside modifying enzymes, AME), produkowane
przez bakterie w celu chemicznej dezaktywacji tych leków. Motywacja˛ do badan´ nad zmu-
towanym miejscem A był brak informacji o zmianach jakie zachodza˛ w fizycznych włas-
nos´ciach miejsca A po róz˙nych zamianach nukleotydów. Wiadomo jakie mutacje prowadza˛
do opornos´ci oraz z˙e nawet pojedyncze zamiany nukleotydu moga˛ miec´ bardzo wymierne
skutki, ale nie wyjas´niono jakie sa˛ tego podstawy. Natomiast, w przypadku AME, celem
prowadzenia symulacji było wyjas´nienie w jaki sposób ta grupa białek jest w stanie byc´
jednoczes´nie bardzo zróz˙nicowana i wysoce specyficzna wzgle˛dem aminoglikozydów.
Przeprowadziłam symulacje dynamiki molekularnej (MD) modelu miejsca A z wybra-
nymi mutacjami oraz reprezentatywnych enzymów z trzech najwie˛kszych rodzin AME.
Aby uzyskac´ opis oddziaływan´ mie˛dzy tymi miejscami wia˛z˙a˛cymi a aminoglikozydami,
przeprowadziłam równiez˙ symulacje MD tych biomolekuł w kompleksach z wybranymi
antybiotykami. W celu analizy symulacji uz˙yłam metodologii z zakresu biofizyki teore-
tycznej. Badałam wiele własnos´ci fizykochemicznych wybranych biomolekuł i ich kom-
pleksów, m.in.: dynamike˛ wewne˛trzna˛, własnos´ci elektrostatyczne, kształt i obje˛tos´c´ miejsc
wia˛zania aminoglikozydów, a takz˙e rodzaje oddziaływan´ z aminoglikozydami. Ponadto,
stworzyłam nowa˛ metode˛ analizy zmian konformacyjnych w molekułach, która dokonuje
podziału biomolekuł na tzw. dynamiczne domeny, na podstawie danych pochodza˛cych z
symulacji lub eksperymentów.
Z analizy symulacji rybosomalnego miejsca A wynika, z˙e mutacje róz˙nych zasad wpły-
waja˛ na róz˙ne własnos´ci fizyczne tego fragmentu RNA. W zalez˙nos´ci od połoz˙enia mu-
towanej zasady, zmieniał sie˛ rozkład ładunków cza˛stkowych w miejscu wia˛z˙a˛cym lub
kształt tego miejsca. Mutacje wpływały równiez˙ na dynamike˛ ruchów wewne˛trznych miej-
sca A. Analiza symulacji cza˛steczek AME wskazała, z˙e oprócz róz˙norodnos´ci struktur trze-
ciorze˛dowych i sekwencji, wyste˛puje w tej grupie równiez˙ róz˙norodnos´c´ w ruchach we-
wne˛trznych. Pomimo tych róz˙nic, wszystkie enzymy oddziaływały z aminoglikozydami w
bardzo podobny sposób, głównie elektrostatycznie. Ponadto, te oddziaływania wydaja˛ sie˛
byc´ kopiowane z kompleksów, jakie aminoglikozydy tworza˛ z miejscem A. Rezultaty moich
badan´ sa˛ zgodne z poprzednimi doniesieniami eksperymentalnymi, a takz˙e pomagaja˛ wy-
jas´nic´ niektóre z nich. Wyniki opisane w tej pracy moga˛ byc´ podstawa˛ do zaprojektowania
zmodyfikowanych aminoglikozydów, które mogłyby byc´ aktywne nawet wobec opornych
bakterii.
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Abbreviations, in alphabetical order
2-DOS = 2-deoxystreptamine;
A-site = aminoacyl-tRNA binding site in the ribosome;
AAC = aminoglycoside acetyltransferase;
ACO = acetyl-coenzyme A;
ADP, AMPCPP, ATP = adenosine diphosphate, adenosine 50-methylenediphosphate,
adenosine triphosphate;
AG = aminoglycoside;
AME = aminoglycoside modifying enzyme;
AMSM = atomic movement similarity matrix;
ANT = aminoglycoside nucleotidyltransferase;
AO = atomic orbitals;
APH = aminoglycoside phosphotransferase;
APO state = here, non-active binary complex enzyme:cofactor;
CG = conjugate gradients (minimization method);
DCCM = dynamic cross-correlation matrix;
DNA = deoxyribonucleic acid;
ESP = electrostatic potential;
GB = generalized Born;
GDP, GTP = guanosine diphosphate, guanosine triphosphate;
GTO = Gaussian-type orbital;
HOLO state = here, active ternary complex enzyme:cofactor:aminoglycoside;
KAN = kanamycin A;
LCAO = linear combination of atomic orbitals;
MD = molecular dynamics;
MIC = minimal inhibitory concentration;
MMGBSA, MMPBSA = molecular mechanics general Born surface area, molecular me-
chanics Poisson-Boltzmann surface area;
MO = molecular orbital;
NMA = normal mode analysis;
NMR = nuclear magnetic resonance;
PAR = paromomycin;
PB = Poisson-Boltzmann (equation);
PCA = principal component analysis;
PDB = Protein Data Bank;
PES = potential energy surface;
PME = particle mesh Ewald;
QM = quantum mechanics;
RESP = restrained electrostatic potential method;
RMSD = root-mean-square deviation;
RMSF = root-mean-square fluctuation;
RNA, mRNA, rRNA, tRNA = ribonucleic acid, messenger RNA, ribosomal RNA,
transfer RNA;
S = svedberg, a measure of sedimentation time of a molecule:
1 S = 10 13 seconds = 100 fs;
SASA = solvent accessible surface area;
SD = steepest descent (minimization method);
WT = wild-type.
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Nucleic acid bases:
A, Ade = adenine;
C, Cyt = cytosine;
G, Gua = guanine;
U, Ura = uracil.
Amino acid names used in the text:
Arg, R = arginine;
ASH = protonated aspartic acid;
Asp, D = aspartic acid;
Asn, N = asparagine;
Gln, Q = glutamine;
Glu, E = glutamic acid;
Gly, G = glycine;
His, H = histidine;
Ile, I = isoleucine;
Lys, K = lysine;
Phe, F = phenylalanine;
Ser, S = serine;
Thr, T = threonine;
Trp, W = tryptophan;
Tyr, Y = tyrosine.

Chapter 1
Introduction
Bacterial cells are typically only several micrometers in size and visible only under a
microscope. Yet there are millions of these cells in every inch of all that surrounds us. Some
bacteria can cause a number of infectious diseases that can be fatal, while others are neces-
sary for human health. Since the 19th century discovery of the connection between certain
diseases and bacteria, there has been constant fight between bacterial survival and human
attempts to eradicate pathogenic bacterial species. The first antibiotic, penicillin, was dis-
covered by Alexander Fleming and was initially highly successful in controlling bacteria.
Evolution, however, enabled bacterial species to resist the antibiotics.1 Their short prolif-
eration time, sometimes as short as minutes,2 and their ability to mutate and incorporate
external DNA, makes their resistance just a matter of time. Recent discoveries point to a
possibility that some tools used by bacteria to subvert antibiotic action were available al-
most from the beginning of life.3
Early antibiotic studies can be called discoveries — among numerous substances a re-
searcher could only hope to find the one that would be lethal to bacteria while having mini-
mal effects towards humans. Today, drug design is used to design inhibitory molecules that
are based on knowledge of the biochemical processes in a bacterial cell. Drug design re-
quires many in-depth studies of the basic mechanisms underlying the modes of action and
resistance towards specific antibiotics in order to explain and clarify the interactions of the
drug inside a bacterial cell and to propose development strategies.
While the final stages of drug development cannot be completed without experiments
on living organisms, modern computational techniques can substantially reduce the time
and cost of the initial stages of drug development. Using the modern tools of theoretical bio-
physics, the interactions between antibiotic molecules and their receptors in bacterial cells
can be reliably investigated with computational modeling.4, 5 Some of these methods enable
detailed studies of static structures, but most importantly, the dynamic features of biomol-
ecules can be directly observed and measured. Theoretical approaches are now commonly
used in research related to drug design.6
Notably, drug development is not only about fighting new diseases. There is a con-
stant need for better antibacterial agents due to the bacterial resistance that develops against
widely used drugs. This is especially important for antibiotics used only in hospitals against
the multidrug resistant bacteria species. One example is the treatment of multi-drug resis-
tant tuberculosis with aminoglycoside antibiotics (AGs),7 which are still successfully used
but the resistance to these antibiotics is spreading. According to the World Health Orga-
nization (WHO), in some regions more than 18% of new tuberculosis cases are multi-drug
resistant.8 Therefore, there is a pressing need to understand how bacteria fight these antibi-
otics, so that better drugs can be designed.
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1.1 Aminoglycoside antibiotics
The history of aminoglycosides began with the discovery of streptomycin in the 1940s
in the laboratory of Dr Selman Abraham Waksman.9 Since then, aminoglycosides have been
successfully used against severe bacterial infections. This class of antibiotics is active against
many species of Gram-positive and Gram-negative bacteria.10 Streptomycin was the first
efficient weapon against deadly tuberculosis, which was an important breakthrough and
brought its discoverer the Nobel prize in 1952.
From the chemical point of view, aminoglycosides are sugar (2-deoxystreptamine, 2-
DOS) derivatives and almost all have a common core, neamine (Figure 1.1). These drugs are
positively charged in physiological pH (ca. 7.4), due to the presence of many NH2 groups,
which become then NH+3 .
11, 12 There are two subclasses of 2-DOS aminoglycosides: 4,5-
disubstituted and 4,6-disubstituted, which are also called neomycin-like and kanamycin-
like, respectively. While these groups share many features, they also have some differences
e.g., in resistance profiles.
Figure 1.1: Chemical structures of exemplary aminoglycosides: (A) neamine, the common core
of most aminoglycosides; the positions of the amine groups are numbered; (B) paromomycin (4,5-
disubstituted 2-DOS); (C) kanamycin and (D) amikacin (both are 4,6-disubstituted 2-DOS).
1.1.1 Mode of action
The primary binding site of aminoglycoside antibiotics is located in the bacterial ri-
bosome. Ribosomes are macromolecular complexes of proteins and RNA13 that provide a
framework for translation process in every living cell (Figure 1.2A). Ribosomes consist of
two parts: the small (called 30S in prokaryota, 40S in eukaryota) and large (50S in prokary-
ota, 60S in eukaryota) subunits, with the names based on subunit sedimentation coefficients.
In prokaryotic organisms, the large subunit consists of two RNA chains (23S and 5S) and
ca. 30 proteins, while the small subunit has ca. 20 proteins and only one RNA chain (16S). At
the interface of these two subunits, there are three binding sites for tRNA molecules, which
provide amino acids according to the mRNA template information. The majority of amino-
glycosides target one of the tRNA binding sites, namely the part of the A-site that is in 16S
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rRNA, i.e., in the small ribosomal subunit14 (Figure 1.3).
The sequence of the 16S rRNA A-site (Figure 1.3B) is highly conserved among dif-
ferent species and displays high similarity even between bacterial and human sequences
(ca. 80%).15, 16 This similarity is responsible for the wide spectrum of aminoglycosidic ac-
tion, however, it also enables these antibiotics to bind to human ribosomes, which can result
in toxicity.17 The most conserved residues in the A-site sequence are two adenines: A1492
and A1493 (numbering as in Escherichia coli is used throughout the text). These residues
form a bulge in this helical rRNA fragment, and in the native ribosome they are very mo-
bile, alternating between the flipped-out and flipped-in states18, 19 (Figure 1.4). This mobility
is needed for the correct recognition of a tRNA molecule that carries an amino acid match-
ing the mRNA codon.20–24 When A1492 and A1493 are in the flipped-out state, they interact
with other parts of the 16S rRNA, and send a signal that the tRNA can be accepted by
the ribosome. When an aminoglycoside is bound, the adenines are locked in the flipped-
out state11, 25–27 (Figure 1.3C), and therefore the acceptance ratio is almost the same for any
tRNA, without differentiation between the cognate, near- and non-cognate. Consequently,
the resulting proteins are malfunctioning, which eventually leads to bacterial cell death (Fig-
ure 1.2B).
Apart from this diminished translation fidelity, some aminoglycosides block the correct
assembly of the ribosomal subunits.9 More recently, another aminoglycoside feature has
drawn attention, wherein binding of some aminoglycosides, e.g., paromomycin, to the ribo-
some allows the translation to proceed past the AUG stop codon on mRNA. This function,
termed a stop-codon read-through ability,28, 29 could be useful in treating genetic diseases
caused by a premature stop codon mutation in humans, wherein ribosomes create trun-
cated proteins that do not function properly. Several modified aminoglycosides have been
proposed that could act in human cells29 to restore the proteins to their native length.
Figure 1.2: Scheme of aminoglycoside action and bacterial resistance. (A) Normal translation pro-
cess; (B) binding of an aminoglycoside (AG) to the 30S subunit increases the translation error rate,
thus producing malfunctioning proteins; (C) specific mutations within the aminoglycoside binding
site result in diminished drug affinity; (D) production of aminoglycoside modifying enzymes (AME)
by bacteria; the chemically altered antibiotics are not able to bind to the ribosomal binding site.
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Figure 1.3: Paromomycin binding site in the bacterial ribosome: (A) cartoon representation of the
entire ribosome during the translation process, with the small subunit in blue (16S rRNA) and cyan
(proteins), and the large subunit in green (5S and 23S rRNA) and lime (proteins), the tRNA molecules
are yellow and paromomycin is presented as red spheres; (B) the sequence of the aminoglycoside
binding site in the E. coli 16S rRNA; (C) paromomycin (shown as spheres) bound to 16S rRNA, the
bases marked yellow are A1492, A1493 (both in the flipped-out state) and A1408.
Figure 1.4: Different conformational states of A1492 and A1493, presented as a visualization of
several X-ray structures of the A-site model or the entire 30S subunit. Each structure is identified by
its PDB code (1J5E,30 1T0E,26 2ET831).
1.1.2 O-target binding sites
Inside the cell, aminoglycosides have a high net positive charge that causes a natural
attraction to negatively charged molecules inside a cell, mainly nucleic acid chains. For
example, it has been shown that aminoglycosides can bind and stabilize DNA triplexes.32
However, it is mainly RNA that interacts with these drugs inside living cells33 and only
specific sequences can effectively bind these antibiotics.34–36 These specific RNAs include
ribozymes (i.e., RNA fragments that are capable of RNA cleavage), aptamers (also called
RNA switches) or even HIV mRNA fragments.37, 38 This binding results in a specific func-
tion, with aminoglycosides affecting the hammerhead ribozyme cleavage39 and inhibiting
viral replication by blocking the necessary conformational changes of viral mRNAs.37
1.1.3 Bacterial resistance
Although aminoglycosides can bind to several different sites in various RNA chains,
their practical use shows that the efficacy in binding to the primary ribosomal binding site
is sufficient to combat bacterial infections. Even though the majority of patients currently
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respond well to aminoglycoside treatment, more and more cases of resistant bacterial strains
are being reported in clinics worldwide.9 One measure of the resistance level is the minimal
inhibitory concentration (MIC; Chapter 2 in Ref.40), which is the lowest concentration of a
drug (in g/ml) needed to completely stop bacterial growth, as determined after a minimum
16 h incubation. For susceptible bacteria, the aminoglycoside MIC is around 5 g/ml but
for resistant strains the MIC can increase by 1000-fold or more (e.g., Refs.41, 42).
There are three main modes of the bacterial resistance to aminoglycoside antibiotics:14, 28
(i) decreasing the number of drug molecules inside the cell (via active and passive efflux);
(ii) changing the primary binding site through mutation or methylation of A-site RNA bases
(Figure 1.2C); and (iii) enzymatic chemical modification of the drugs (Figure 1.2D). The last
two modes are the main focus of this thesis, and are introduced in the two following sections.
1.1.4 A-site modications
Aminoglycosides target the very basic process in bacterial cells, thus the majority of
the spontaneous mutations within the binding site are lethal for bacteria.43, 44 Moreover,
there are usually several copies of genes encoding 16S rRNA14 so that even when one RNA
copy carries a resistance-causing sequence, the others remain susceptible. Experiments have
shown that only specific mutations result in living resistant bacteria with even single-point
mutations being sufficient to promote survival41, 42, 45–47 (Table 1.1 presents exemplary mu-
tations together with their MIC values).
Table 1.1: Level of resistance caused by exemplary mutations in the bacterial 16S rRNA.
See Figure 1.3B for base numbering.
MIC [g/ml]
mutation paromomycin kanamycin A amikacin reference
WT 1 1 1 41
A1408G 64 >1024 >1024 41, 48
G1491A 32 2 1 41, 48
G1491U 512 128 32 41, 48
U1406C 64 32–64 4 41, 49
U1495A 256–512 512 128–256 41, 49
U1406C/U1495A >1024 >1024 1024 41, 49
U1406C/U1495G >1024 >1024 128 41, 49
The most important difference between bacterial and human A-site sequences is at base
1408, which is adenine (A) in prokaryota and guanine (G) in eukaryota.50 Bacteria with
an A1408G mutation are highly resistant (i.e., having a broad resistance profile) and their
proliferation rate is almost the same as for the wild type.51 There are many other muta-
tions that give high levels of resistance, however, they also lead to diminished translation
efficiency, which prolongs the time of bacterial growth. Moreover, not every mutation is
equally efficient against every aminoglycoside — different distribution patterns of OH and
NH2 substituents in aminoglycosides correlate with different resistance profiles of bacteria
(e.g., Refs.41, 42, 52). Nevertheless, the double mutation U1406C/U1495A gives a very broad
resistance profile.45 Interestingly, a similarly broad profile was found in bacteria possess-
ing only one of these two substitutions, namely U1495A, while the other single mutation,
U1406C, did not produce significant effects. Although some mutations result in high levels
of resistance, they are not common among bacteria. Researchers have demonstrated that
the most frequently occurring mutations are also the most profitable,51 i.e., they decrease
the efficiency of aminoglycosides significantly while not slowing down bacterial growth.
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Nevertheless, only a few bacterial species can use this resistance method, namely these
species that possess only one copy of the gene encoding the 16S rRNA chain. More recently,
post-transcriptional methylation of this RNA fragment was shown to cause resistance in
several Gram-negative pathogens.53, 54 This is an even smaller change than a single-point
mutation but it still can produce high levels of resistance (MIC> 256 g/ml53), albeit against
fewer aminoglycosides.
Figure 1.5: Schemes of reactions catalyzed by representative AMEs from different families:
(A) acetyltransferase AAC(60), (B) nucleotidyltransferase ANT(40), and (C) phosphotransferase
APH(30,500). The aminoglycoside being modified is kanamycin A and the affected substituents are
marked in red.
1.1.5 Aminoglycoside modifying enzymes
The most commonly occurring method of counteracting aminoglycoside action is for
bacteria to produce proteins that chemically modify these drugs, aminoglycoside modify-
ing enzymes (AMEs).14, 55 Thus modified drugs cannot bind to the primary binding site in
16S rRNA.56 There are a plethora of these enzymes55 since the majority are chromosomally
encoded and specific for one bacterial strain. In general, all AMEs can be divided into three
families, depending on the type of reaction they catalyze: (i) (aminoglycoside) acetyltrans-
ferases (AACs), (ii) nucleotidyltransferases (ANTs), and (iii) phosphotransferases (APHs).
These enzymes require a cofactor to work: nucleoside triphosphate (commonly ATP) for
APHs and ANTs, and acetyl-coenzyme A (ACO) for AACs. Additionally, ANTs and APHs
need divalent ions (most often Mg2+) bound in the vicinity of the cofactor phosphate groups.
These families are further divided into groups and types, depending on which aminoglyco-
side substituent they modify and from which bacterial strain they are derived. For example,
APH(6)-Ia modifies the 6-OH group of ring II, and originates from Streptomyces griseus [Dis-
tler et al., 1987 in Ref.55]. Figure 1.5 depicts how one aminoglycoside, kanamycin A, can be
modified by different AMEs.
Notably, these three AME families are not related in terms of their sequence, structure
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or evolution. With regard to structure, the AAC family can be assigned to the GCN5-related
N-acetyltransferase (GNAT) superfamily,57 while the function of APH enzymes links them
to the protein kinase family,58 although the sequence similarity between these two groups is
very low. ANTs are unrelated to any other known enzymatic group. Below, we present the
current state of knowledge for three selected enzymes that represent the different families:
AAC(60)-Ib, ANT(40)-I and APH(30,500)-IIIa.
Figure 1.6: Visualization of selected AME structures and kanamycin A. (A) Kanamycin A is shown
as sticks and colored according to the atom type: C — green or magenta, N — blue, O — red, H
— white; the dashed circles mark the substituents modified by selected AMEs: (B) AAC(60)-Ib, (C)
ANT(40), and (D) APH(30,500)-IIIa. In panels (B–D), the proteins are presented in cartoon, the ligands
are represented as van der Waals spheres: kanamycin A in green, ATP (or ACO in the case of AAC)
in dark blue. The ANT structure is composed of two symmetrical parts and only one is colored.
AAC(60)-Ib (Figure 1.6B) has a unique sequence among acetyltransferases, but its ge-
netic location within mobile elements makes it the most widespread enzyme of the AACs.55, 59
While almost all aminoglycosides can form complexes with AAC(60)-Ib, only those possess-
ing the 60-NH2 group can be modified,60 such as neamine, kanamycin A or amikacin in
Figure 1.1, but not paromomycin. Through site-directed mutagenesis of this enzyme, the
amino acids crucial for its enzymatic activity and folding were identified.61–64 Structurally,
AAC(60)-Ib resembles other enzymes from the family,60, 65 but it differs in that it is active
only as a monomer.
ANT(40)-I (Figure 1.6C) is a promiscuous enzyme, conferring resistance to many amino-
glycosides55 and accepting different cofactors.66 The available information for this enzyme
is rather scarce. It has been shown that the nucleotide binds after an aminoglycoside,67
which is a unique feature among all AMEs. The two X-ray structures (ANT(40)-I without66
and with the substrates68) are the only structural data available for the enzymes from this
family. Apart from those data, NMR experiments showed that this enzyme is relatively rigid
and thus some aminoglycosides have to adjust their conformation upon binding.67
The last enzyme, APH(30,500)-IIIa (Figure 1.6D), is commonly found in Gram-positive
bacteria.55 Experimental mutagenesis studies58, 69–71 highlighted the amino acids that are
the most important for the reaction it catalyzes. It has been shown that the drug binds after
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ATP and magnesium ions.72 By comparing available APH(30,500)-IIIa X-ray structures, the
conformational changes of the enzyme before and after complexation with an aminoglyco-
side could be studied,73–75 and the binding poses of different antibiotics compared.76, 77
Through a comparison of the available static structures of AME:AG complexes,67, 78–80
some aminoglycosides were found to be dynamic inside the binding sites, while others
changed their conformation upon binding, but the majority were found to adopt the same
conformation as in the ribosomal A-site. This finding, unfortunately, hampers the process
of designing modified aminoglycosides that would have a higher affinity towards the RNA
binding site than towards AMEs.
1.2 Computational studies of aminoglycosides
and their binding sites
Aminoglycoside antibiotics and their biological partner, RNA, have been a subject of
many different computational studies. One of the first simulations concerning aminoglyco-
sides was conducted by T. Hermann and E. Westhof,81 who showed that when these drugs
bind to a hammerhead ribozyme, the positions of their amine groups match those of the
Mg2+ cations that are bound to the ribozyme during a normal cleavage. These cations are
required for proper ribozyme folding and functioning, thus when the antibiotic is bound
instead, the ribozyme is no longer active.
Concerning the primary binding site of aminoglycosides, the rRNA A-site, Réblova
et al. analyzed the internal motion of helix 44 from 16S rRNA, which contains the A-site.82
These all-atom MD studies showed that adenines A1492 and A1493 are flexible, alternating
between the flipped-in and flipped-out states. There was also a transient hydrogen bond-
ing between A1492 and A1408, when A1492 occupied the flipped-in conformation. Inter-
estingly, only base 1492 was observed in the flipped-out conformation. A more complete
view of the adenine flipping was presented in a study by K. Y. Sanbonmatsu83 that used
an enhanced sampling method, called Replica Exchange MD, to demonstrate that adenines,
A1492 and A1493, are in a dynamic equilibrium between the flipped-in and flipped-out
states, which agreed with previous experiments.18, 19 These simulations also suggested a
lower energy barrier for the transition of A1492 than for A1493. Another MD simulation
study compared the adenine mobility between the free A-site and a complex with an amino-
glycoside.20 The researchers proposed an explanation for aminoglycoside action, where the
binding of aminoglycoside narrows the range of movement of A1492 and A1493, render-
ing these bases incapable of functioning as the differentiating factor between cognate and
non-cognate tRNAs.
Several all-atom molecular dynamics (MD) studies of aminoglycosides complexed with
the A-site have been performed. Vaiana et al. showed that the A-site:PAR complex is
stable and the interactions between the antibiotic and RNA are mostly electrostatic, but
water-mediated hydrogen bonds were also found to be important.84 Our previous stud-
ies expanded these findings by comparing the A-site internal dynamics of wild-type and
eukaryotic-like structures (i.e., possessing the A1408G mutation).85 Results from our MD
simulations showed that this mutation caused a change in the mobility of A1492 and A1493
and also affected the electrostatic potential inside the binding cleft. Another study of the
A-site complexes with different aminoglycosides revealed a correlation between the hydra-
tion pattern around the bound drug and their computed binding affinity.86 This work also
described how the dynamics of the U1406U1495 base pair is affected by various antibiotics.
Finally, Replica Exchange MD was used to study binding and unbinding of an aminoglyco-
side to and from the A-site.87 Results from this study concluded that the steering mechanism
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for the RNA:AG association is stochastic gating rather than induced fit, as was proposed ear-
lier. This means that it is not the antibiotic that pushes the adenines A1492 and A1493 to the
flipped-out state. Rather, the aminoglycoside has to wait for this state to occur in order to
bind.
A more coarse-grained approach was used to investigate the association pathways for
aminoglycosides approaching the A-site model88 and the whole 30S ribosomal subunit.89
The results from these Brownian dynamics simulations described the driving forces of this
association, wherein aminoglycosides appear not to find their 30S binding site immediately
but instead they scan the surface for the right match. During the final steps of complex
formation, the rate of association depends on both, electrostatic and steric interactions.
Finally, a binding free energy analysis has been reported90 that combined experimental
and computational methods. A detailed electrostatic analysis of both, the A-site model and
the whole 30S subunit, showed that the existing models and methods that calculate the
electrostatic contribution to the binding free energy yield reliable results, however, specific
adjustments to the parameters are sometimes necessary.
In the case of AMEs, only two computational studies have been reported: of AAC(20)-Ic91
and AAC(3)-IIIb.92 This research, however, focused not on aminoglycosides but on the co-
factor binding and dynamic response of the enzymes.
1.3 Motivation of the research
The Infectious Diseases Society of America published a new call in 2010, encourag-
ing organizations and scientists to develop ten new antibiotics by the year 2020.93 In 2011,
World Health Day, organized by WHO, was dedicated to drug resistance. These two or-
ganizations, among others, pointed out the diminishing focus of industry on antibacte-
rial innovation, which resulted in only a few new antibiotics introduced to the market in
2010, with most being slight modifications of older drugs. One reason for this decreased
output is the cost of developing a new drug, which is estimated to be on average several
billions USD.94 However, another reason is the poor understanding of bacterial resistance
mechanisms. Some general schemes are known, but their details often remain unclear. The
scientific project presented here seeks to describe the detailed mechanisms of bacterial re-
sistance against aminoglycosides and can help speed the development of better antibiotics
from this class.
In the case of aminoglycosides, the resistance methods developed by bacteria are not
new. To date, many modified aminoglycosides have been proposed in the hope that they
would have higher potency against resistant bacteria.95 Modifications to the drugs in-
clude addition and/or substitution of chemical groups in known aminoglycosides (e.g.,
Refs.96–101), fusion of aminoglycosides with other antibiotics (e.g., Ref.102) or even de novo
re-design of compounds having similar features.29 However, the majority of these modified
drugs, even if they are active in vitro, fail to pass the in vivo tests, which emphasizes the need
to extend our knowledge on the processes occurring inside bacterial cells.
The above mentioned experimental studies on the A-site mutations revealed the correla-
tion between specific base substitutions and effectiveness of different aminoglycosides.45–47
However, these studies could not explain the underlying physical and chemical changes
that led to such an effect. Thus, the question can be posed: how does a change in only one
base substantially alter the susceptibility profile of a bacterium? Using molecular modeling
of the mutated 16S rRNA A-site fragments and their dynamics, we searched for changes
that could explain this phenomenon.
www.who.int/world-health-day/2011/en/index.html
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Furthermore, while there have been extensive studies of aminoglycoside modifying
enzymes in terms of kinetics and the thermodynamics of the chemical reactions they cat-
alyze,14, 55 the general lack of structural data for AMEs coupled with their diversity, makes
computational studies of these enzymes difficult. This structural, functional and sequence-
related diversity of AMEs is in stark contrast to their narrow specificity towards the amino-
glycosides, which are a homologous group of antibiotics. This contradiction was the driv-
ing force of the second part of the research presented here, which compares representative
AMEs according to the way they interact with aminoglycosides and seeks to identify simi-
larities within their binding site features.
1.4 Research aims and tools
The main aim of the thesis is to compare and contrast physical features of the dif-
ferent aminoglycoside binding sites to shed light onto aminoglycoside resistance mech-
anisms at an atomic level. We have used a biophysical technique called molecular dynam-
ics (MD) to investigate the dynamics of aminoglycosides and their complexes with their
pharmacologically-relevant primary binding site, 16S rRNA A-site model, and AME repre-
sentatives: AAC(60)-Ib, APH(30,500)-IIIa and ANT(40)-I.
The all-atom simulation of the prokaryotic A-site model enabled us to study the internal
movements of this rRNA binding site, and specifically the bases that are responsible for the
fidelity of translation and aminoglycoside binding. Next, we conducted simulations of the
A-site model with specific nucleotide mutations, to look for changes in the physicochemi-
cal properties that these mutations introduce. The simulations of the bare mutated A-site
models were complemented with the simulations of their complexes with aminoglycosides.
Thus, our computational analysis could be compared with the experiments that provide
data on bacterial resistance due to A-site mutations. Finally, we studied the dynamics of the
AME representatives and compared the interactions formed with aminoglycosides in these
different enzymes. Moreover, we related these interactions to those found in the rRNA
binding site.
We used the MD simulations to characterize the dynamics of the selected biomole-
cules that bind aminoglycosides. There are many ways of analyzing MD simulations, and
sometimes different tools must be used to examine proteins and nucleic acids. We have
investigated different physical and chemical properties of the simulated systems: hydro-
gen bonding networks, residue fluctuations, patterns of internal motions, density of water,
shape of binding pockets and energetics of aminoglycoside binding. MD simulations were
complemented with other biophysical techniques such as the Poisson-Boltzmann model to
investigate the electrostatics of the systems, principal component analysis (PCA) to iden-
tify differences in biomolecular conformations, and molecular mechanics (MM) generalized
Born (GB) solvent accessible (SA) approximation of the binding free energies of the com-
plexes. In addition, we developed a new method that identifies dynamic domains based on
a set of molecular conformations and helps describe the conformational changes occurring
in biomolecules.
Chapter 2
Methodology
We studied the dynamics of aminoglycosides and selected biomolecules that bind them
inside a bacterial cell. Moreover, we investigated and compared the interactions that were
formed in the complexes of these different biomolecules with aminoglycosides. This aim
required use of a variety of computational tools. We employed MD simulations to study
the internal motions of the molecules, but we also analyzed static X-ray structures with
the use of Poisson-Boltzmann continuum electrostatic theory. The parameterization of the
aminoglycoside molecules required application of quantum calculations. We used several
methods to analyze the output of MD simulations — some were already implemented in
the available software and for some types of analyses we prepared our own scripts. In
addition, we also developed a new algorithm and software to study the internal motions
of biomolecules based on their conformations. This chapter presents the theory behind our
research. The software we used is listed in the next chapter, section 3.4 Data analysis, and the
newly developed software is described in Chapter 4, section 4.1 New method for identifying
similarly moving atoms in molecular conformation sets.
2.1 Quantum calculations of electrostatic potential
In order to create an atomic model of a biomolecule, first one needs a set of coordinates
for each atom. Typically, this is provided by experiments, X-ray analysis of crystallized bio-
molecules or nuclear magnetic resonance (NMR) studies in solid-state or solutions.103 The
Protein Data Bank (PDB)104 stores the results of these experiments and provides a uniform
description of biomolecular conformations.
The atomic positions are not enough, though, if one wants to study how the atoms
interact with each other. Here comes in physics. The proper, quantum mechanical (QM)
approach requires taking into consideration interactions between each pair of the subatomic
particles in each atom, which is enclosed in the Schrödinger’s equation (Chapter 2 in Ref.105):
H^	(~R;~r) = E	(~R;~r) ; (2.1)
where H^ denotes the full Hamiltonian of the studied system (i.e., the operator combining
potential and kinetic energies); 	(~R;~r) is the wave function, dependent on positions of the
nuclei (~R) and of the electrons (~r); and E is the total energy of the system.
Solving the Schrödinger’s equation is, however, infeasible even for a powerful com-
puter for any biologically relevant biomolecule, which contains several tens or hundreds of
atoms. However, one can notice that a nucleus of an atom moves much more slowly than
electrons, due to its larger mass. Thus, when considering nuclei as static particles, only
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electron wave functions need to be calculated — this forms the Born-Oppenheimer approx-
imation (see e.g., Chapter 6 in Ref.105 or Chapter 9 and 10 in Ref.106):
H^el
(~r;~R)
	el
(~r;~R)
= Eel	el
(~r;~R)
; (2.2)
which describes the movement of electrons (~r) for a given static configuration of nuclei (~R).
This assumption is valid only for atoms in their electronic ground state. The wave func-
tion for an electron (	el) is dependent on the coordinates and spin value. The part that is
controlled by the coordinates is called the atomic orbital (AO).
Having described one atom, a problem appears when one wants to describe a molecule,
i.e., a set of atoms that are connected in a precisely defined way through chemical bonds.
An approach used here is called the molecular orbital theory (MO; e.g., Chapter 8 in Ref.105
or Ref.107), where the electrons originating from each atom are spread and mixed within
the molecule, so that each of them contributes to each bond. This enables to ignore the
relativistic effects and to present the wave function of a molecule as a linear combination of
the wave functions of its atoms (LCAO, linear combination of atomic orbitals):
	mol =
∑
a
ca 	a ; (2.3)
where index a traverses all atomic orbitals within the molecule; and ca are numerical coef-
ficients.
Thus, to describe a molecule, the coefficients ca have to be found. This is obtained
through the self-consistent field method (e.g., Chapter 8 in Ref.105 or Ref.107), where an
initial guess is successively corrected until another iteration does not change the total en-
ergy of the molecule. In this method, for the description of the atomic orbitals, one uses
base functions, commonly Gaussian-type functions. The standard basis sets are built from
linear combinations of Gaussian-type orbitals (GTO). For example, the basis 6–31G* 108 de-
scribes the orbital closest to the nucleus, with a linear combination of six GTOs (6-31G*);
next, the other electrons are described by two combinations of three and one GTO, respec-
tively (6–31G*); additionally, the asterisk (6–31G*) denotes that more accurate calculations
are provided for heavy atoms, where higher orbitals are included through the so-called po-
larization functions.109 The mentioned basis set has been demonstrated to perform excellent
for aqueous solutions of biomolecules.110
Having found 	mol, one can calculate the total energy, Emol, from Equation 2.2, and
then the electrostatic potential (ESP, ) around a molecule:
Emol =  grad  : (2.4)
The obtained ESP can then be used for assigning partial charges to each modeled atom
that best reflect the QM-derived ESP. First, the guessed charges are used to calculate the ESP,
which is then fitted, through the least-square fitting procedure, on the correct QM ESP. This
method is called restrained electrostatic potential method (RESP).110 Sometimes a simpler
method is used, where charges are assigned to atoms based on precalculated values stored
in database. The charges are chosen to match the atom and bond type. One of the best mod-
els is called AM1-BCC,111, 112 which gives charges comparable to those obtained through
quantum calculations on the 6–31G* basis set.113, 114
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2.2 Molecular mechanics and force eld
For larger molecules, it is more convenient to ignore the discrimination between the
movement of electrons and nuclei, since electrons can adapt to the movement of nuclei very
fast. Within the Born-Oppenheimer approximation, we can describe a molecule as a set of
classical particles, with certain radii and point charges, that interact with each other. With
such an approximation, one can combine all the “observable” chemical interactions into an
equation describing the potential energy of a given molecular configuration, called the force
field (FF; e.g., Chapter 7 in Ref.105 or Chapter 8 in Ref.115):
VFF = Vbond + Vangle + Vtors + Vimpr︸ ︷︷ ︸
bonded interactions
+ Vel + VvdW︸ ︷︷ ︸
non bonded interactions
: (2.5)
The bonded interactions are usually approximated by harmonic potentials:
Vbond =
∑
1 2
Kb (b  b0)
2 ; (2.6)
Vangle =
∑
1 2 3
K ( 0)
2 ; (2.7)
Vtors =
∑
1 2 3 4
K [1 + cos (n  (   0))] ; (2.8)
Vimpr =
∑
1 2 3 4
K (   0)
2 ; (2.9)
while the non-bonded terms are:
Vel =
∑
i;j
qiqj
40rij
; (2.10)
VvdW =
∑
i;j
"ij
(R ijmin
rij
)12
  2
(
R
ij
min
rij
)6 ; (2.11)
where rij is the distance between atoms i and j ; "ij is a well-depth, which indicates of a
magnitude of favorable interactions between atoms i and j ; and the parameters include:
• force constants for: the bonds (Kb [kcal/(molÅ2)]), angles (K [kcal/(molrad2)]), tor-
sional angles (K [kcal/mol]) and the improper torsional angles (K [kcal/(molrad2)]);
• equilibrium constants for: the bonds (b0), angles (0), torsional angles (0; see Fig-
ure 2.1A) and improper torsional angles ( 0; Figure 2.1B);
• the periodicity parameter (n);
• partial atomic charges (qi; qj );
• equilibrium distances between two atoms that are not connected through a chemical
bond (R ijmin; Figure 2.1A).
All the parameters are given values based on experiments (spectroscopy or NMR) and quan-
tum calculations (e.g., Ref.116 or Chapter 8 in Ref.115), and they depend on the types of the
atoms that form the interaction.
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Figure 2.1: Illustration of the force field components. See the text for description.
2.2.1 Energy minimization
The potential energy of a molecule depends on its conformation, i.e., the positions of
all atoms. As has been mentioned, these initial positions used in simulations are typically
obtained from experiments. However, the X-ray derived structures lack coordinates for
hydrogen atoms, and therefore these have to be added in silico. Moreover, usually one adds
also water and ions, to reproduce the natural environment of a molecule. This addition can
result in some atoms being too close to each other. Therefore, a minimization of energy is
conducted prior to any other calculations. During the minimization, the atoms are being
slightly repositioned so as to reach the minimal potential energy of the whole system.
There are several algorithms for finding this minimum — in our simulations, two of
them were used, namely the steepest descent (SD) and conjugate gradients (CG) algorithms.
These fall into the category of linear descent search algorithms (see Chapter 10 in Ref.115),
for which a general scheme is outlined below.
General linear descent search algorithm:
1. at a given point ~xi of the potential energy surface (PES) calculate the energy E(~xi) and
its gradient ~gi = grad E(~xi);
2. create a search vector ~si (dependent on the type of algorithm);
3. move on PES along ~s:
~xi+1 = ~xi + i~si ; (2.12)
4. calculate the new energy E(~xi+1) and the energy difference: E = E(~xi+1)  E(~xi);
5. repeat the above steps until E < ".
In the above scheme, both i and " are very small but non-zero real numbers. In order
to obtain the best i value, the line-search algorithm is used. Using Equation 2.12, three
different movements (for three different i values) along ~si are generated, and the energy in
these new points is calculated. Then, a polynomial is fitted to this set of points E(i). The
minimum of this polynomial gives the best i parameter for a given step.
SD and CG algorithms differ only in the definition of the search vector ~s. In SD it is
based only on the current point in PES: ~s SDi =  ~gi= j~gij; while the CG version depends on
the previously chosen search vector and the current gradient: ~s CGi =  ~gi= j~gij + i ~s
CG
i 1 ,
where i is a constant dependent on the current and/or previous gradient vector, and it is
specific to each implementation of the CG algorithm.115
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The SD algorithm performs better when the search for the minimum is in the initial
stage, but when being already close to the minimum, this approach can result even in step-
ping over the minimum and continuing to the other slope of PES. This is undesirable, and
therefore, commonly, the minimization is started with SD and continued with CG, because
the latter algorithm performs better near the minima.117
2.3 Molecular dynamics
2.3.1 Theory behind
With such a representation of the biomolecule and the interactions between its atoms,
one can now proceed to calculate the forces:
~F =  grad
(
V(~x)
)
; (2.13)
which would lead to movement, according to the Newton’s equation:
~F = m  ~x : (2.14)
The analytical solution of the above equation, however, includes integrals, which are diffi-
cult to implement in a computer, thus several approximate algorithms have been developed.
The positions in consequent time steps, ~x(t t) and ~x(t+t), are expressed through Taylor
approximations truncated to the forth order terms (e.g., Ref.118 or Chapter 7 in Ref.105):
~x(t + t)
Taylor
= ~x(t) + t ~v (t) +
1
2
t2 ~a(t) +
1
6
t3 +O(t4) ;
~x(t   t)
Taylor
= ~x(t)  t ~v (t) +
1
2
t2 ~a(t) 
1
6
t3 +O(t4) :
Addition and subtraction of the above equations yields, respectively:
~x(t + t) = 2~x(t)  ~x(t   t) + ~a(t) t2 +O(t4) ;
~v (t) =
~x(t + t)  ~x(t   t)
2t
+O(t2) ;
where ~x, ~v  _~x are the position and velocity of an atom; t is the timestep; and ~a  ~x
denotes acceleration, which can be obtained from Equation 2.14. This forms the so-called
Verlet algorithm,118 which is very efficient and gives accurate positions of atoms (O(t4)).
However, one of the disadvantages of the Verlet algorithm is that the velocities are com-
puted with relatively large errors (O(t2)), and therefore sometimes another approach is
used, called leap-frog,118 which provides better estimation of the velocities. In the leap-frog
algorithm, an additional mid-point of the timestep is created to facilitate the evaluation of
the mutually dependent positions and velocities:
~x(t + t) = ~x(t) + ~v (t + 1=2t) t ;
~v (t + 1=2t) = ~v (t   1=2t) + ~a(t) t:
As mentioned previously, the initial positions are given, but the initial velocities have to
be somehow assigned. Most often, these are randomized values from the standard Maxwellian
velocity distribution, which are generated based on a number created from the current date
and time, in order to minimize the probability of repetition.118 The sequence of atomic posi-
tions, velocities, and accelerations yields an MD trajectory.
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Figure 2.2: Exemplary function for the
Lennard-Jones-type van der Waals in-
teractions (solid light grey line): when
the atoms i and j are approaching each
other, the energy becomes attractive, un-
til the atoms are within the optimal dis-
tance (R ijmin), from which the repulsive
term is the dominant one. The switch-
ing function (dashed line), which can be
turned on at switchdist point, helps
to smooth the switch of the potential en-
ergy to zero for distances larger than the
cutoff point.
In order to precisely calculate the movement, one needs to have a good approximation
of the conformation-dependent potential energy from the force field. The only difficulty
is the calculation of the non-bonded interactions, which in principle should be computed
for each pair of the atoms, regardless of their distance. This would bring, however, huge
computational costs when simulating larger biomolecular systems. One can see from Equa-
tions 2.10 and 2.11 that these non-bonded terms are small enough at large distances to be ne-
glected without much loss of precision. The van der Waals interactions decline as fast as r 6,
and therefore the standard approach for computing these interactions is to set a cutoff dis-
tance parameter — above this value, this non-bonded term is set to zero. To allow a smooth
transition, one can also utilize a switching function from a set switchdist distance to the
cutoff (Figure 2.2). When the two parameters are set reasonably, the calculations are faster
and the precision is maintained.
The electrostatic interactions diminish much slower than the van der Waals terms (r 1),
and therefore, typically, a different approximation is used, called particle mesh Ewald (PME)
summation.119 The short-range electrostatic interactions are computed explicitly, through
Equation 2.10, in the Euclidean space, while the long-range ones are calculated in the Fourier
space:
Vel =
∑
i;j
ffi(~xj   ~xi) = Vshort   Vlong ; (2.15a)
Vshort =
∑
i;j
ffishort(~xj   ~xi) ; (2.15b)
Vlong =
∑
~k
~ffilong(~k)
∣∣∣~(~k)∣∣∣2 ; (2.15c)
where ffi is the electrostatic potential, and ~ffi, ~ are the Fourier transforms of the electrostatic
potential and of the charge density, respectively. Each of these functions, Vshort and Vlong,
quickly converges to zero in their own space, thus it is sufficient to take into account only a
couple of first terms when calculating these interactions.
As with all physical models of reality, the problem of boundary conditions exists. Ide-
ally, our biomolecule of interest would be surrounded by an infinite amount of solvent (we
do not consider here models that do not require solvent, nor simulations of membranes,
which form a natural boundary). The infinity is, of course, nonreproducible, and therefore,
in the classical MD simulations, the entire finite box with the solvent and the solute is copied
— an approach called periodic boundary conditions (PBC; illustrated in Figure 2.3; see e.g.,
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Figure 2.3: Periodic boundary conditions. The
simulated system is finite (the cell in the middle)
but the coordinate system is “wrapped” so that
each particle moving beyond the border of the sys-
tem appears at the opposite side with the same ve-
locity.
Chapter 12 in Ref.115). Hence, all the atoms are surrounded by other atoms, which prevents
the atoms near the edge from “escaping”, and if an atom moves towards the edge of a box,
it would simply appear at an opposite edge, moving with the same velocity. In practice, the
minimum image convention is used, where the trajectory of only one copy of the system (N
atoms) is recorded, and each atom is allowed to interact only with the other N   1 atoms
that are in the closest copy.
2.3.2 Simulation setup
The MD simulation protocol is composed of several steps:
minimization, described in section 2.2.1;
thermalization, when the temperature of the simulated box is slowly raised to a desired
one (commonly to the room temperature, 300–310 K);
equilibration, this step lets the molecule and the solvent “get used to” the higher tempera-
ture and it is the last preparation step;
production, where the main data is gathered for a subsequent analysis; this step is the
longest one — depending on the size of the system and available computational power,
it can last from tens to thousands of nanoseconds.
Importantly, the above list is only a scheme of the process — for each of the simulated
biomolecule, one has to adjust this scheme in order for the simulations to yield reliable and
reasonable results.
Thermalization is required because the initial coordinates describe molecules at a dif-
ferent temperature — the one that had been used in the experiment (e.g., typically  100 K
for the X-ray studies120); while the simulations are usually conducted at room temperature
( 300 K). Equilibration is also necessary, since in this step the density of the solvent is being
leveled so that the whole simulated box is filled equally. Moreover, the conformation of a
molecule obtained from X-ray studies can be slightly different than its conformation in the
physiological conditions due to different forces in the crystal (crystal packing artifacts120).
During the production stage, when no specific constraints are imposed on the simula-
tion conditions, the simulation revolves in the microcanonical ensemble,118 also called NVE
because of the three constants: the number of atoms (N), the volume (V) and the energy (E).
This is a natural setup but some systems or aims require a different ensemble. Moreover,
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the numerical errors and implementation issues may result in a rise of temperature and/or
energy if the simulation parameters were not adjusted to a given system. In this research,
the NVE ensemble was used for relatively short simulations of compact proteins. The elon-
gated RNA fragment was, however, simulated in the NPT ensemble. Because of its higher
flexibility and being a fragment of a much bigger construct, it was more natural to apply the
constant pressure (P) and temperature (T) in this system. A simulation in the NPT ensemble
is also termed Langevin dynamics (see Chapter 13 in Ref.115 or Ref.121), due to the Langevin
equation used to describe the forces:
m  ~x(t) =  V(~x(t))    m _~x(t) + ~Fr(t) ; (2.16)
where  is the collision parameter [1=s], which defines the friction; and ~Fr(t) denotes an
additional random force that is generated from a Gaussian distribution:〈
~Fr(t)
〉
= 0 ; (2.17a)〈
~Fr(t)~Fr(t = 0)
〉
= 2kBT0 m  (t) ; (2.17b)
where kB is the Boltzmann constant and (t) is the Dirac delta function. These stochastic
additional forces mimic collisions between the solute and solvent molecules, which, as can
be seen in Equation 2.17b, provides a coupling to a heat bath with a set temperature of T0.
The timestep in the simulations has to be large enough to obtain long trajectories that
would allow to observe biologically relevant motions, but short enough to reproduce all
the interactions correctly. Therefore, the optimal step is connected to the most vibrating
bonds, i.e., bonds with hydrogen atoms. These are movements lasting approximately 10 fs
(frequencies of around 3000 1=cm 122). Therefore, usually the timestep is set to a one order
higher value of 1 fs. This can be extended to 2 fs when putting harmonic restraints on these
bonds formed with hydrogen atoms, as it is e.g., in the SHAKE algorithm.123
2.4 Basic molecular dynamics data analysis
MD simulations produce nowadays a lot of data that has to be carefully analyzed. The
most basic quantities are the temperature and the energy of the simulated system. In the
classical MD these values should stay leveled in the production phase; therefore, the first
check of the stability of the simulation is to visualize the time dependence of these values.
The energy and temperature would naturally rise during the thermalization and equilibra-
tion but should hit a plateau in the production stage.
However, the most important data obtained from MD simulations are the positions of
atoms versus time. These constitute sometimes even hundreds of thousands of conforma-
tions of a studied molecule or complex. There are many ways one can analyze these data,
depending on what the aim of the research is and what types of approximations were used
in the model. However, the first and basic analysis is to observe whether the molecule is
internally stable. Unless one performs a simulation of folding or unfolding, the global con-
formation of the structure should be maintained if the simulation was prepared correctly.
The standard procedure is to calculate the global root-mean-square deviation (RMSD) of
atomic positions from the reference structure, which is commonly the starting one.
RMSD(t) =
√√√√ 1
M
n∑
i=1
mi j~xi(t)  ~xi(0)j
2 ; (2.18)
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where M = ni=1mi; mi denotes the mass of atom i; n is the total number of atoms in the
molecule; ~xi(t) shows the position of atom i in timestep t; and ~xi(0) points to the starting
position of atom i.
Another measure of compactness of the structure is the radius of gyration, Rgyr:
Rgyr(t) =
√
M
∣∣~xi(t)  ~xCOM(t)∣∣2
M
; (2.19)
where ~xCOM(t) is the position of center of mass (COM) at timestep t. This gives a rough
estimate of the size of the sphere that would contain the given structure, and therefore, the
bigger the radius, the less compact the conformation.
Naturally, in the initial stages of the simulation, i.e., minimization, thermalization and
equilibration, RMSD and Rgyr should rise because the structure changes along with changes
in the surrounding environment (raising temperature, interactions with added solvent or
ion molecules, etc.). However, in the production stage these values should rather oscillate
around a certain mean value, which indicates that the molecule maintains its native, folded
state.
There might be, however, differences in the mobility of various fragments of a biomole-
cule. Another standard measure, root-mean-square fluctuations (RMSF), shows how much
each of the atoms or residues (i.e., amino acid or nucleotide) moves in the simulation, with
regard to its average position:
RMSF(i) =
√√√√ 1
T
T∑
t=1
j~xi(t)  h~xiij
2 ; (2.20)
where i enumerates the residues or atoms; T is the total simulation time; and h~xii denotes
the mean position of atom i. These values can be compared with the experimental -factors
(temperature factors [Å2]), which are parameters used by crystallographers to refine the
structure (e.g., Chapter 7 in Ref.120). A -factor tells us how much the atom in the crystal
fluctuates isotropically around its position in the model — if that value is large (more than
50 Å2), the position of the atom in the model is not well defined, and therefore, one can
expect high mobility of this atom in the MD simulation.
2.5 Describing internal motions
The measures described above, although quite crude, can indicate a biologically signif-
icant event, e.g., a conformation change or large differences in mobility between biomolec-
ular fragments. The identified event often must be more thoroughly examined using some
more advanced tools.
2.5.1 Principal Component Analysis
The raw data from an MD simulation constitute of fluctuating atoms, which can appear
chaotic and difficult to quantify. A well known physical method can help to emphasize
the main directions of internal collective molecular motions. Principal component analysis
(PCA) reduces the dimensionality of the movements and finds their main modes.124 This is
done by, first, calculating the covariance matrix, C^ :
Cij =
〈
M
1
2
ii
(
xi   hxii
)
M
1
2
jj
(
xj   hxji
)〉
; (2.21)
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where M^ denotes a diagonal matrix with masses of atoms (in case of weighted covariance
matrix) or an identity matrix; xi is the ith coordinate, out of total 3n coordinates (n is the
number of atoms); and hxii is the average value of xi.
This matrix is then diagonalized, in order to find the internal coordinate system:
R^T C^ R^ = diag (1; 2; : : : ; 3n) (2.22)
where R^ denotes an orthonormal invertible matrix, whose columns are eigenvectors of C^ ;
and i is the ith eigenvalue (1  2  : : :  3n).
Then, the trajectory can be projected onto the eigenvectors (also called modes or princi-
pal components, PCs):
~p(t) = R^T M^
1
2
(
~x(t)  h~xi
)
(2.23)
Each mode pi(t) has an associated eigenvalue i, which reflects the value of mean-square
fluctuations (Equation 2.20). The couple of modes with the largest eigenvalues describe the
most significant motions.
2.5.2 Conformer plots
This description of motions in terms of internal coordinates can be used to compare
different conformations and trajectories of the same molecule. Due to the decreasing or-
der of eigenvalues, the two or three first modes are sufficient to distinguish between some
important conformational changes within the structure. Thus, already plotting the relation
between PC 1 and PC 2 often gives interesting insights. This is especially useful when there
are many conformations and/or trajectories to analyze, since in a plot of PC 1 vs. PC 2 one
conformation would be depicted as one dot.
Not only the modes defined by PCA can be plotted like that. In fact, one can define any
type of internal coordinates, depending on the studied system. The idea behind is still the
same — to reduce the dimensionality of the observed conformational changes.
2.5.3 Correlated motions
Sometimes, one would like to know how exactly the conformations differ between
themselves, which parts of a molecule change their positions. One approach is to calculate
the dynamic cross-correlation matrix (DCCM, C^ 0):125
C 0ij =
Cij
Nij
=
h~di  ~djiMD√
h~dii
2
MDh
~dji
2
MD
; (2.24)
where C^ is the covariance matrix from Equation 2.21; N^ denotes the normalizing matrix;
vector ~di  ~xi(t)   h~xii shows the deviation of atom i from its mean position; and h iMD
denote an average over the whole trajectory.
The correlation matrix is symmetric (i.e., C 0ij = C
0
ji) and C
0
ij 2 [ 1; 1]. The high positive
values describe the correlated motions (i.e., two atoms are moving in the same direction
at the same time), while values close to  1 point to anti-correlated motions. However, it
can be shown that this method loses some information, namely, it does not accounts for
the correlated rotations because of averaging over the Cartesian space. Let us consider two
points, a = ra(cos; sin) and b = rb(cos; sin), that rotate around a common point
(Figure 2.4). Their trajectories can be described by the distances from the center (ra and rb)
and the angles (ffii): a = ra(cos( + ffii); sin( + ffii)) and b = rb(cos( + ffii); sin( + ffii)).
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Figure 2.4: Example of a correlated ro-
tation. This kind of correlation is dif-
ficult to detect with a standard cross-
correlation matrix.
Equation 2.24 would then yield a correlation coefficient: C 0ab  cos(   ), which therefore
cannot be used to state whether the motions are correlated or not. There are, of course,
other notations (spherical coordinate system, Euler angles), which would deal better with
rotations, but they are much more complicated to implement.
In order to provide a better description of how fragments of the molecule move in re-
lation to one another, we have developed an algorithm and a software, Geometrically Sta-
ble Substructures (GeoStaS), which divides a biomolecule into “dynamic domains”. Each
molecular fragment that appears internally rigid but moves with relation to another frag-
ment, constitutes one dynamic domain. Our algorithm identifies also a correlated rotation
shown in Figure 2.4. The details of the new algorithm and its implementation are given in
Chapter 4, Section 4.1 New method for identifying similarly moving atoms in molecular conforma-
tion sets.
2.6 Intra-molecular interactions
When describing the changes either in a conformation of a molecule or in a relative
orientation of two molecules forming a complex, the simplest way is to analyze hydro-
gen bonds that are formed and/or destroyed. Hydrogen bonds can be direct or mediated
through a water molecule. The two chemical moieties between which a hydrogen bond can
Figure 2.5: Examples of non-covalent interactions. (A) Hydrogen bonds are formed between the
donor (here: oxygen atom, colored red) and the acceptor (here: nitrogen atom, colored blue), through
the hydrogen atom (colored silver). The geometrical definition states that the distance d should be
less than 4 Å and the angle  2 [120; 180]. (B–C) Stacking interactions enhance stability and are
formed between two aromatic rings — here, two neighboring nucleic bases from a helix are shown
(B) from the side and (C) from top. The optimal distance, h, is  4 Å.
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be formed are called a donor and an acceptor (Figure 2.5A). The donor has at least one free
electron pair, while the acceptor has to be able to “accept” an electron, i.e., is covalently
bonded to a hydrogen atom. The formal definition of a hydrogen bond126 is based on a
distance between the donor and the acceptor and an angle between the three bond-forming
atoms. The closer the angle is to 180, the stronger the hydrogen bond. While the distance
varies depending on the atom type of the donor and acceptor, it is typically less than 4 Å.
Thus, monitoring the distance and angle between possible donor–acceptor pairs is a simple
way of quantifying hydrogen bond networks during an MD simulation.
Another important non-bonding interaction type is stacking (Figure 2.5B–C), formed
between two parallel aromatic rings. In an aromatic ring, the so-called delocalized elec-
trons from  orbitals form an electron cloud over and under the ring. The two clouds from
two rings interact with each other through the stabilizing London dispersion forces and re-
pulsive interactions between multipoles. Stacking is very important especially in nucleic
acid structures, where the stacked nucleic bases stabilize e.g., the double helix (Chapter 8 in
Ref.127). In most of the force fields, this effect can be reproduced through the van der Waals
interactions. The geometrical definition of the stacking is based on the distance between the
two rings, which should stay around 4 Å.128 The van der Waals attractive force diminishes
quite fast for larger distance, and it becomes very quickly repulsive when atoms are closer
(see Equation 2.11). When trying to find stacking interactions in a simulated molecule, not
only the distance has to be taken into account — one has to check whether the rings are in
a parallel orientation. This can be done by constructing vectors (~a and ~b) perpendicular to
the planes of the rings (A and B) and calculating a cosine of an angle between them:
AjjB , cos
(
](~a; ~b)
)
 f1; 1g ; (2.25)
~a?A ; ~b?B :
2.7 Electrostatic description
2.7.1 Poisson-Boltzmann model
One of the very basic features of a molecule is its electrostatic potential (ESP). To calcu-
late the ESP for large biomolecules, such as proteins or nucleic acids, one often uses contin-
uum electrostatics theory. This theory is based on the nonlinear Poisson-Boltzmann equation
(PB):129, 130
r  [(~x)r(~x)] =  4 solute(~x)  4
ni∑
i=1
qici exp
(
 qi(~x)
kBT
)
; (2.26)
where r is a divergence operator; (~x) describes the position-dependent dielectric func-
tion; (~x) is the ESP at position ~x; solute(~x) denotes the charge density of the solute and
the Boltzmann distribution total(~x) =
∑ni
i=1 qici exp ( qi(~x)=kBT ) is used to describe the
solvent charge density, coming from ions (ni is the number of all ion types, each with charge
of qi); ci denotes the concentration of ions of type i; kB is the Boltzmann constant.
Solving Equation 2.26 gives us (~x), but the analytical solution is not possible for arbi-
trary shaped objects such as biomolecules. Therefore, several methods have been developed
to obtain the numerical solutions of PB equation, including the finite-difference or boundary
element methods.129, 131 Sometimes, the full PB equation can be approximated by its linear
version, which is obtained when the exponent in the charge distribution in Equation 2.26
is approximated by a Taylor series truncated to the first-order term exp ( qi(~x)=kBT ) 
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1   qi(~x)=kBT . This holds when the energies are much smaller than the thermal energy,
qi(~x)fi kBT , which can be assumed for dilute solutions or monovalent electrolytes. Then,
the electrostatic energy (GPB) of a given biomolecular conformation can be found through a
“charging” process:
GPB =
1
2
∫
(~x) (~x) d~x : (2.27)
2.7.2 Generalized Born model
However, even with such an approximation the calculations for hundreds of confor-
mations of a biomolecule can be too time- and resource-consuming to conduct. Therefore,
one may choose another approximation, where a molecule is built of many non-overlapping
spheres with point charges. This enables to represent the electrostatic solvation free energy
through the use of the well-known Born formula for each of the spheres:131
Gi;GB =  
(
1 
1
sol
)
q2i
2a
; (2.28)
and the total electrostatic energy for the molecule would be:
GGB '  
(
1 
1
sol
)
1
2
∑
i;j
qiqj
fGBij
; (2.29)
where sol is the dielectric constant of the solvent; the summation includes all the “atom”
pairs in the molecule; and fGBij is a function of the distance between atoms i and j , and of the
effective Born radii of the atoms, Ri. In the GB approximation this effective radius depends
not only on the radius of atom i but also on radii and positions of other atoms. Therefore,
when creating the force field parameters for the molecule, one should include these specific
effective radii in the parameterization. The main issue with the GB method is its applica-
bility mainly to spherically symmetric systems, due to the formulation of Equation 2.28.
Recently, however, a method has been developed that includes a scaling factor for the Born
radii of the atoms buried beneath the surface of a molecule.132 This approach yields the
electrostatic energies comparable to those obtained with the PB method but is much faster.
2.8 Assessment of the binding free energy
When analyzing a structure of a complex, it is often desired to know how well the
molecules fit to each other, which can be measured by their free energy of binding. This
value is especially important when performing calculations associated with the drug design
process. Sometimes the two compared complexes may behave similarly in a simulation, but
there can be a difference in the binding free energy, which could point to a potentially better
drug. One of the methods used with biomolecular simulations to estimate the binding free
energies is MMPBSA or MMGBSA, which is named after the division of the total free en-
ergy into terms calculated through Molecular Mechanics, PB (or GB), and solvent accessible
surface. This method is outlined below.
The binding free energy is naturally defined as a difference between the free energy of
the complex and its substrates separately, thus first the free energies of the receptor and the
ligand that form the complex have to be calculated. According to thermodynamics, the total
energy available in an isolated system (also known as Gibbs free energy, G) is combined of
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enthalpy (H) and entropy (S) (see e.g., Chapter 8 in Ref.133):
G = H   T  S : (2.30)
The enthalpic part is connected to the internal chemical properties and the energy of inter-
action with the solvent, thus it can be assessed by the force field energy value (also called
molecular mechanics term, VFF ) and the solvation energy (GPBSA or GGBSA):129, 134
H = VFF + GGBSA : (2.31)
The solvation energy is computed through submerging the molecule in an implicit solvent
medium, even though the simulations were performed with atomic representation of the
water. That is due to implicit models being less computationally demanding and incor-
porating all the features of the discrete model (such as hydrophobicity or a high dielectric
environment) but averaged. Also, one does not need to worry about boundary conditions,
since in the calculations the implicit solvent can be assumed infinite. The solvation energy
is thus obtained as follows:129, 134
1. all the molecular charges are zeroed in vacuum;
2. the uncharged solute is solvated;
3. all charges are restored in the implicit solvent environment.
Therefore, the solvation energy can be dissected into:
GGBSA = GSA  Wvac +Wsol ; (2.32)
where GSA and Gpol =  Wvac +Wsol are the non-polar and polar terms, respectively; Wvac
and Wsol denote the work needed for discharging the molecule in vacuum and re-charging
it in solvent, respectively.
The polar term is calculated as described in Section 2.7 Electrostatic description. The non-
polar part above is estimated by the solvent accessible surface area (SASA) of the molecule:
GSA =   SASA, where  [kcal/(molÅ2)] is the surface tension.
The entropic part from Equation 2.30 is associated with the level of order in the struc-
ture, i.e., how rigid it is. This term is much more difficult to calculate. There are several
approximations, including the quasi-harmonic approximation135 or based on the normal
mode analysis.136 All these methods, however, become unreliable when a big conforma-
tional change upon binding is anticipated. This is the case with aminoglycosides, which
have many rotatable bonds, thus their conformation can be significantly altered when form-
ing a complex. In our calculations, after several trials, we decided not to include the entropic
term, and therefore the resulting values serve only as a comparison and cannot be treated as
absolute.
MD simulation provides multiple conformations, and for each of those the free energy
value can be computed and then averaged (hGi). Then, the final binding free energy is
obtained:
G = hGcomplexi  
(
hGreceptori+ hGligandi
)
: (2.33)
Although, generally this type of calculation does not yield absolute values, when comparing
the resulting energy for different complexes their order is the same as for the experiments
(e.g., Refs.86, 90). Therefore, the MMPB(GB)SA method is often used for a rough estimation of
the binding free energy but it is especially valuable in a detailed investigation of the contri-
butions of individual residues (see e.g., Refs.137–139). This energy can be easily decomposed
into terms that originate from specific residues. This kind of information is helpful when
designing modifications of drugs.
Chapter 3
Parameterization and preparation of
the simulated systems
The main aim of this study was to investigate aminoglycoside antibiotics recognition
and to provide insight to the underlying mechanisms of bacterial resistance. MD simula-
tions were conducted on a number of systems to study the interactions between amino-
glycoside and RNA binding site models, as well as the representative modifying enzymes.
Below, the details of the simulation preparation steps are outlined.
3.1 Aminoglycoside binding site in ribosomal RNA
3.1.1 Starting structures
In the cellular environment, aminoglycosides bind to the 30S ribosomal subunit14 (see
Figure 1.3). The entire 30S subunit is a large nucleoprotein complex of about 100 000 atoms30
and all-atom MD simulations of the entire 30S subunit are extremely computational de-
manding even at the nanosecond timescale. However, it has been shown that these an-
tibiotics also bind to fragments of this subunit, specifically to the models of the A-site.140, 141
Moreover, the thermodynamic features of this binding process are almost the same as for the
binding to the whole 30S subunit.140, 141 One of the A-site models is a symmetrical construct
of two aminoglycoside binding sites, thus it can accommodate two drugs (Figure 3.1A),
which immediately increases the statistics of observations (we can assume that there is no
mutual dependence of these binding sites, since they are divided by eight canonical base
pairs).84, 90, 141
We chose the complexes of the model A-site with two aminoglycosides, paromomycin
(PAR, PDB ID: 1J7T,142 resolution of 2.5 Å) and kanamycin A (KAN, PDB ID: 2ESI,31 reso-
lution of 3.00 Å). These two drugs represent the two classes of aminoglycosides: 4,5- and
4,6-disubstituted 2-DOS (see Figure 1.1B–C). The complex of the A-site with kanamycin A
was simulated in order to have a reference for the subsequent simulations of aminoglyco-
side modifying enzymes (described below). The complex with PAR was subjected to in silico
mutations (presented in Figure 3.1B). We have chosen those mutations that introduced high
level of resistance, especially against paromomycin, as reported in the experiments on whole
bacteria (referenced to and described in Table 3.1). Also the A1408G mutation confers high
resistance in bacteria (see Table 1.1). We studied this mutation as a separate project and the
results have been published previously.85 Here, we focus on some other base substitutions.
All types of simulations concerning the A-site are listed in Table 3.1.
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(A) Starting structure for the RNA simulations (B) Sequence of the A-site
Figure 3.1: The RNA A-site model used in the simulations: (A) The whole model (PDB ID 1J7T)
complexed with paromomycin (PAR). (B) The sequence of the A-site with marked mutations that
were studied here.
Table 3.1: MD simulations of RNA and the abbreviations used.
simulation of RNA simulation
with AG(a) without AG time [ns](b) effect of introducing mutation
WT_PAR WT 20 —
G1491A_PAR G1491A 20 A is found in eukaryotic sequence15, 16 and
confers resistance against paromomycin (up
to 64-fold increase in MIC values46, 48)
G1491U_PAR G1491U 20 high resistance against paromomycin (512-
fold increase in MIC42)
U1495C_PAR U1495C 20 resistance against paromomycin (128-fold in-
crease in MIC in M. smegmatis42 and 5-fold in-
crease in T. thermophilus46)
U1406C/U1495A_PAR U1406C/U1495A 20 high resistance against many aminogly-
cosides (>1000-fold increase in MIC for
paromomycin42, 49)
WT_KAN — 25 —
(a) see Abbreviations on page 18;
(b) duration of each production stage.
3.1.2 Preparation of the simulated systems
Hydrogen atoms were added to all the models: we assumed the standard protonation of
the nucleotides at pH 7.4 and the aminoglycosides in a fully protonated state (i.e., all amine
groups became NH+3 ).
12 The systems were subsequently neutralized by adding sodium
ions (Na+) in the electrostatic potential minima with the LEaP program from Amber 9143 (or
Amber 11144 in the case of WT_KAN simulation), resulting in 44, 34 and 36 ions added to the
bare RNA, complexes with PAR and the complex with KAN, respectively. The neutralized
systems were then submerged in water boxes of dimensions 926969 Å3 using the TIP3P
water model.145 Finally, random water molecules were substituted for 39 Na+ and 39 Cl 
ions, to create the ionic strength of 150 mM, which resembles the cellular environment.
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In the crystal structure used for the WT_KAN simulation an additional KAN molecule is
bound non-specifically. This was removed from the structure prior to the system setup.
For all the RNA systems we have used the Amber ff99146 force field. Parameters for the
antibiotics were prepared in Amber and the parameterization process is described below, in
Section 3.3 Free aminoglycosides.
3.1.3 Simulation conditions
The simulation protocol was specifically designed for a system containing short RNA
helix. Due to complicated RNA architectures and high charge, the procedure has to be
different than for proteins.147
1. The minimization was performed by sander program from Amber: 8 000 steps of
SD and 2 000 steps of CG. All heavy atoms (i.e., not hydrogens) were restrained with
harmonic position constraints (with constraint coefficient k = 100 kcal=(molÅ2)).
2. During the thermalization, temperature was gradually increased from 30 to 310 K
and the constraints were weakened to k = 50 kcal=(molÅ2) for the first 85 ps, and
k = 25 kcal=(molÅ2) for the next 35 ps.
3. Next, there was the two-step equilibration: during the first 300 ps the constraints were
gradually weakened and for the last 600 ps only the terminal nucleotides
(k = 0:35 kcal=(molÅ2)) plus the phosphate atoms (P; k = 0:25 kcal=(molÅ2)) were
assigned small constraints. The values of these constraints was adjusted so as to match
the thermal fluctuations (i.e., the -factors) for the analogous atoms from the crystal
structure of the whole 30S subunit (PDB id: 1IBK148).
4. The last stage, production, was performed with the same constraints as for the second
equilibration step, and lasted 20 or 25 ns (see Table 3.1). In the tests, the removal of
constraints on terminal nucleotides resulted in fraying ends, and because in the whole
ribosome, the A-site is contained within a longer helix, we did not want to allow for
the fraying termini.
The simulations were performed in NAMD149 in the NPT ensemble: the temperature
was controlled by Langevin thermostat (collision frequency of 1 per ps), and the pressure
(1 atmosphere) was maintained using the Langevin piston method.121, 150 Electrostatic inter-
actions were calculated using PME,119 and a cutoff of 12 Å was used to limit the direct space
sum. The SHAKE algorithm123 was used to constrain all the bonds with hydrogen atoms,
which enabled a 2-fs long timestep.
3.1.4 Choice of the force eld
The simulations of RNA were conducted in ff99 Amber force field. During our study
newer force fields parameters became available, namely the ff10151–153 model, with an im-
proved description of the torsional angles for the sugar–base ( angle) and sugar–phosphate
( and  angles) linkages in long simulations (> 50 ns). Our trajectories were, however,
shorter (maximum 25 ns), and therefore, the used parameters should not bias the outcome.
Banáš et al.152 have shown that simulations of RNA in ff99 could lead to a severe disruption
of the secondary helical structure, due to misparameterized  angle. However, throughout
our simulations, we have not observed the described switch of  values from   150 to
  90 (the mean value calculated for all the residues for the whole simulation time reached
maximum of 132 for the G1491U simulation). Moreover, recently we have also performed
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100 ns-long simulations of the bare RNA A-site model in both ff99 and ff10, and the analysis
of the  angle showed no difference for the first 50 ns (data not shown).
3.1.5 Reliability of the dynamics of the A-site model
Inside the small ribosomal subunit, the A-site interacts with other parts of the ribosome,
thus the internal dynamics of the nucleotides observed in MD simulations of the isolated
A-site model could in principle differ from their behavior in the whole ribosome. To inves-
tigate the structural environment of the bulged bases A1492 and A1493 inside the ribosome,
we gathered known ribosomal structures from PDB and calculated the solvent accessible
surface areas (SASA) of these bases. Figure 3.2 shows that the majority of the X-ray SASA
values are within the range or larger than the values measured in the MD simulation of the
free A-site. The only points that are lower than the MD-derived values originate from the
ribosomal complexes with the drugs binding in the A-site or in its immediate vicinity, which
naturally diminishes the solvent accessibility of A1492 and A1493. Thus, following the pre-
vious experimental studies140, 141 and our analysis, we assumed that this short fragment of
16S rRNA constitutes a reasonable model for our studies.
Figure 3.2: Solvent accessible surface area (SASA [Å2]) of the adenines A1492 and A1493 in dif-
ferent ribosomal X-ray structures (identified by their PDB codes on the x axis); some ribosomal
structures contain ligands bound in the A-site neighborhood, which significantly decreases the SASA
values. The right panel shows the histogram of SASA values measured in the simulation of the wild-
type (WT) A-site model.
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3.2 Aminoglycoside modifying enzymes
3.2.1 Starting structures
From all structures of AMEs available in PDB, we have chosen their complexes with
aminoglycosides that had a resolution below or equal to 2.5 Å. For the MD simulations
only three of them were taken, each one from a different AME family. Table 3.2 lists all the
structures chosen for further studies.
To make the simulations comparable, we had to modify some of the selected structures.
In the complex of AAC(60)-Ib (PDB ID 1V0C), kanamycin C was present instead of kanamy-
cin A. Two substituents were swapped to regain kanamycin A: 60-OH and 20-NH2. Also in
this enzyme, there were three amino acids missing: Gly 71, Glu 72, and Glu 73, located in the
loop above the aminoglycoside binding region. Initial positions of these residues were taken
from another X-ray structure, 2BUE, which contained the same enzyme but complexed with
a different aminoglycoside.
The structures of two other enzymes, APH(30,500)-IIIa (PDB ID 1L8T) and ANT(40) (PDB
ID 1KNY), contained the appropriate antibiotic, but an inactive form of the cofactor: AM-
PCPP and ADP, respectively. In the case of ANT, the change into the active cofactor (ATP)
involved changing only one atom from C to O. In the case of APH, a phosphate group was
added to the ADP molecule.
Table 3.2: Structures of AMEs that were used in the study.
PDB ID enzyme cofactor aminoglycoside ions reference
1V0C AAC(60)-Ib (y*) ACO kanamycin C Ca2+ 60
2BUE AAC(60)-Ib ACO ribostamycin Ca2+ 60
1L8T APH(30,500)-IIIa (y*) ADP kanamycin A Mg2+ 74
1KNY ANT(40) (y*) AMPCPP kanamycin A Mg2+ 68
1L8T APH(30,500)-IIIa (y) ADP kanamycin A Mg2+ 74
1J7L APH(30,500)-IIIa (y) ADP — Mg2+ 74
1S3Z AAC(60)-Iy (y) coenzyme A ribostamycin — 154
1M4I AAC(20)-Ic (y) coenzyme A kanamycin A — 60
(*) initial structures for the simulations
(y) structures analyzed with the use of APBS and Surface Diver
3.2.2 Preparation of the simulated systems
We wanted to perform the simulations under conditions similar to the cellular envi-
ronment (pH 7.4), and therefore, kanamycin A was in a fully protonated state (i.e., with
all amine groups being NH+3 ).
12, 155 For proteins, adding hydrogen atoms was not straight-
forward. Initially, we used the PDB2PQR server156 together with the PropKa software157
(version 1.0) to determine the protonation states of every amino acid in the unliganded en-
zymes. Employing the same approach for the structures complexed with kanamycin A re-
sulted in protonation states of the residues of the enzyme that disfavored the formation of
important hydrogen bonds with the ligand. Inside the binding sites of AMEs, many Glu
and Asp residues create an environment that can be too complicated for automated pre-
dictors, such as PropKa. These specific protonation states in such environments have been
studied12, 67, 158, 159 and it has been shown that this is connected with partial protonation of
an aminoglycoside during its binding to an enzyme. Hence, we have decided to manually
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Table 3.3: MD simulations of representative AMEs.
system description(a) simulation name length [ns]
AAC + ACO
{
+ KAN AAC_HOLO 3 x 20
  KAN AAC_APO 3 x 20
APH + ATP
{
+ KAN APH_HOLO 3 x 20
  KAN APH_APO 3 x 20
ANT + ATP
{
+ KAN ANT_1KAN 3 x 20
+ 2 x KAN ANT_HOLO 3 x 20
  KAN ANT_APO 3 x 20
(a) Molecules are described by abbreviations (see Section Abbreviations on page 18). See Table 3.2 for
details of the structures.
place hydrogen atoms of the residues inside the binding sites, based on experimental data
and visualization of the structures. As a result, all of the Glus and Asps were negatively
charged, like in water environment, apart from Asp 50 (named ASH) in both monomers of
the ANT dimer, which was assigned a neutral state.
Each of the initial structures was neutralized by addition of sodium ions, Na+, and sub-
merged in a truncated octahedron of TIP3P water molecules. The minimal distance between
the solute and the edge of the system was 15 Å.
3.2.3 Simulation conditions
We used the newest available Amber force field dedicated for proteins, ff03.r1.160, 161
The simulations were performed with the use of pmemd (Particle Mesh Ewald Molecular
Dynamics) and sander programs from Amber11 suite. The simulation protocol was the
following:
1. The minimization consisted of two parts: (i) 3000 steps of SD search and 2000 steps of
CG algorithm with harmonic restraints on the solute (force constant of 2.0 kcal/(mol Å2));
(ii) afterwards, no constraints were applied, the whole system underwent 7000 steps
of SD search, followed by 3000 steps of CG.
2. The minimized structures were then subjected to slow heating to 300 K during 50 ps
of MD with restraints on the solute (force constant of 2.0 kcal/(mol Å2)).
3. The following equilibration stage was also two-fold: (i) during the first 50 ps con-
straints of 2.0 kcal/(mol Å2) were applied to the solute; (ii) for the remaining 1 ns the
constraints were four times smaller. Equilibration was performed in the NPT ensem-
ble, with Langevin thermostat and isotropic position scaling for the constant pressure.
4. The main part, production stage was performed in the microcanonical ensemble (NVE).
A timestep of 1 fs was used together with a lower tolerance of the SHAKE algorithm
(10 6 Å, restraining water hydrogen atoms only), in order to ensure a stable temper-
ature. The electrostatic calculations were performed with the PME approach with a
one order lower tolerance of the direct sum (10 6), which decreases RMSD of force
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errors.144 Both, the temperature and the total potential energy were stable, with fluc-
tuations around the mean of less than 0.5% and 0.01%, respectively.
For each of the systems, the simulation was repeated three times, each time with differ-
ent initial velocities. This increases the sampling of the molecular conformational space and
the statistical relevance of the findings. Table 3.3 presents a summary of all the simulations.
3.3 Free aminoglycosides
3.3.1 Simulation setup
Simulations of the two aminoglycosides, paromomycin (4,5-disubstituted DOS) and
kanamycin A (4,6-disubstituted DOS), were performed in explicit water, in order to check
the correctness of the parameterization. The initial positions of the atoms of the drugs were
taken from the structures of their complexes that had the best resolution: 1J7T142 for PAR
(2.5 Å), and 1ND4162 (2.1 Å) for KAN. Almost all of the amine groups of paromomycin12, 163
and kanamycin A155 have pKa values> 7:4, which means that these are protonated at phys-
iological pH. The pKa value of one substituent, namely group 3-NH2 in both of these antibi-
otics (see Figure 1.1), was found to be slightly lower than 7 in water, however, it was shown
that the environment of the RNA A-site or enzymes promotes full protonation of aminogly-
cosides.12 Thus, for the simulations of the drugs alone, we have added hydrogens to all of
their amine groups, in order to use these structures and parameters in the simulations of the
complexes. This resulted in the total charge of +5 and +4 for PAR and KAN, respectively.
The parameters were based on GAFF (General Amber Force Field).164 For paromomy-
cin, the partial atomic charges were taken from a standard set called AM1BCC.165 In the case
of kanamycin A, charges were fitted by antechamber with the RESP algorithm, based on
the electrostatic potential calculated by Gaussian166 with the GTO 6–31G* basis set.
Both drugs were neutralized by adding chloride ions, Cl , prior to putting them into
a truncated octahedron of TIP3P water molecules. The minimal distance between the drug
and water edge was 15 Å. The simulations of aminoglycosides were carried out with the
use of sander from Amber11. The protocol was essentially the same as for the simulations
of the enzymes. We performed three simulations per aminoglycoside, each one with dif-
ferent initial velocities, each production lasting 10 ns. The length of each simulation was
short because our aim was only to validate the force field parameters and not to thoroughly
investigate the conformational phase space of these molecules.
3.3.2 Parameterization validation
Aminoglycoside antibiotics posses several rings that are connected through flexible
linkages (see Figure 3.3). The different conformations they adopt can be quantified by mea-
suring the dihedral angles of the atoms in the linkages, as proposed in Refs.52, 167 The gen-
eral definitions are: ffi(H1sugar–C1sugar–O1sugar–Cx) and  (C1sugar–O1sugar–Cx–Hx), where
“x” depends on the linkage. For example, for linkage I/II in kanamycin A: ffi(H10–C10–O10–
C4) and  (C10–O10–C4–H4); see Figure 3.3B for the numbering of atoms. Figure 3.4 shows
the results for the two studied aminoglycosides; the measurements were done for MD simu-
lations in explicit water. Each linkage has one conformation that is the most populated, but
the range of the observed dihedral angles is quite wide. Importantly, linkage I/II behaves
similarly for both studied antibiotics. This is expected, since rings I and II are common to the
majority of aminoglycosides. These two drugs, however, belong to two different subgroups
— kanamycin A is a 4,6-DOS, while paromomycin is a 4,5-DOS. Therefore, linkages II/III
scan different parts of the ffi/ conformational space.
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(A) paromomycin (B) kanamycin A
Figure 3.3: Starting structures of the two aminoglycoside representatives, shown as sticks, colored
by atom type: C — magenta or green, N — blue, O — red and H — white. The rings are numbered
with Arabic numbers and the atoms referred to in the text are labeled.
Figure 3.4: Conformations of the studied aminoglycosides, (A) kanamycin A and (B) paromomycin
(only the representative conformations are shown), measured by dihedral angles of linkages: (C),(E)
linkage I/II, (D),(F) linkage II/III, and (G) linkage III/IV.
There were no experimental data exactly for paromomycin, thus we have compared the
MD-derived values with the NMR data for neomycin B,167 which differs from paromomy-
cin only in one substituent (60-NH2 instead of 60-OH). Moreover, these experiments were
conducted at pH values of 4.7 and 9.7, while in the simulations, we mimicked pH 7.4. The
NMR experiments52, 167 showed that linkage I/II for both aminoglycosides acquired most
often a syn- orientation (  0), and the population of anti- orientation (  180 or
   180) had a different pH dependence for these two drugs. In the case of kanamy-
cin A, the anti- orientation was sampled most often at low pH, and it diminished at high
pH. On the contrary, for neomycin B, only at high pH the anti- orientation of linkage I/II
was measurable. In the simulations, we observed only the syn- orientation (Figure 3.4C,E).
Linkage II/III was found to acquire only syn- orientation for kanamycin A,52 while
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for neomycin B the anti- orientation was sampled for 17% of the cases.167 Moreover, in
experiments, the neomycin B linkage II/III occupied a non-exo conformation (i.e., ffi value of
  10) for 35% of the time. We observed the same scheme for kanamycin A and paromo-
mycin in the MD simulations; however, the occupancy of the non-exo conformation in par
was lower (only  6%; Figure 3.4D,F). Finally, the measured  angle for linkage III/IV of
neomycin B167 was close to 50 for half of the sampled conformations, and close to  50 for
the other half. In the simulations, paromomycin linkage III/IV sampled the conformations
with  2 [ 30; 70] more often then the conformations with  2 [30; 70] (45% vs. 23%)
(Figure 3.4G).
In addition, we measured the distances between the selected hydrogen atoms and com-
pared them with the experimental data.52, 167 Figures 3.5 and 3.6 present the experimental
and MD-derived distances for paromomycin and kanamycin A, respectively. In the case of
paromomycin, we found that the distances 7 and 10 are larger in our simulations than in
the experiment. These refer to the relative orientation of rings II and III (Figure 3.4F), where
the occupancy of the non-exo conformation in the simulation was much higher in the exper-
iment than in our simulations, probably due to limited sampling. Moreover, for a similar
reason distance 13 was larger in the simulation than in the experiment. In general, however,
the average MD distances were in sufficient agreement with the NMR experiments.
In the case of kanamycin A, the agreement between the experiment and the simulations
was good, except for the distances 2 and 6, which were larger in the simulations. This is most
probably caused by no anti- conformations sampled in the trajectories (Figure 3.4C–D), in
which these distances are shorter.
Overall, for the purpose of our simulations of aminoglycosides in the complexes with
the RNA A-site and AMEs, the force field parameters seem good enough. The starting
conformations of aminoglycosides were taken from the X-ray structures of the complexes,
and the short simulations were conducted only to ensure that the parameterization was
reliable, not to study the conformational transitions of these drugs.
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Figure 3.5: Distances between chosen hydrogen atoms of paromomycin, averaged over the trajecto-
ries, compared with the values from an NMR study of neomycin B, which differs from paromomycin
only with one chemical group (6-OH instead of 6-NH2). The experimental values are taken from
Table 1 in Ref.167 and are numbered as follows: 1 stands for the distance between H10 and H4,
2 — H10–H5, 3 — H10–H3, 4 — H10–H500, 5 — H10–H200, 6 — H10–H300, 7 — H100–H5, 8 — H100–H4,
9 — H100–H6, 10 — H200–H6, 11 — H100–H400, 12 — H1000–H300, 13 — H1000–H200, 14 — H1000–H400. See
Figure 3.3A for atom labeling. The asterisks (*) mark the distances for which only lower bounds were
given in the experimental study.167
Figure 3.6: Distances between chosen hydrogen atoms of kanamycin A — a comparison of values
obtained from the simulations and NMR experiments at pH 7.7, as shown in Figure S2 in Ref.52 The
H-H distances are numbered as follows: 1 stands for the distance between H10 and H4; 2 — H10–H3;
3 — H10–H5; 4 — H100–H6; 5 — H100–H5; 6 — H100–H1. See Figure 3.3B for atom labeling.
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3.4 Data analysis
For visualization of the trajectories, we used VMD168 and PyMol Molecular Graphics
System (Schrödinger, LLC., www.pymol.org). The plots and graphs were produced in the
R environment.169 VMD was also used to measure the following quantities (through custom
Tcl/Tk scripts):
 the dihedral angles;
 the average density of water or ions inside the binding sites;
 SASA;
 and the stacking interactions.
The basic measures, i.e., RMSD and RMSF, were calculated with either g_rms and
g_rmsf programs of the GROMACS package170–172 or ptraj of AmberTools. ptraj was
also used for the following analyses:
 clustering of conformations: average linkage method was used; we performed this hierar-
chical clustering till all the clusters were merged and then we chose the number of clusters
that would give the optimal distribution of the conformations, based on the methodology
described in Ref.;173
 finding hydrogen bonds between the ligand and the receptor; maximal distance between the
donor and the acceptor was set to 3:5 Å and the angle was minimum 120;
 measuring distances between atoms or centers of mass of residues;
 outputting the average conformations.
To analyze the tertiary structures of the simulated RNA, we used the 3DNA software,174
which measures various helical parameters of nucleic acids, including the glycosidic angle
 , the number of hydrogen bonds between bases in a pair or the opening angle of a base
pair. The method is based on a geometrical analysis and comparison of the nucleotide con-
formation from the simulation to a template structure.
From the pharmacological point of view, the volume of a binding pocket is an important
feature of a receptor because it can be critical when designing drugs and checking their
efficiency. It is easy to find and define a binding pocket on a surface of a protein (e.g., Ref.175),
but it is not straightforward for RNA structures since there are many cavities on a surface
of e.g., a double helix. We have chosen the POVME software176 for calculating the volume
of binding sites because it offers a generic approach and the area of the binding pocket
can be precisely defined by the user. The implemented algorithm measures the volume of a
chosen cavity by placing beads on a grid wherever the bead does not contact any atom of the
molecule. Thus, the sum of placed beads times the grid resolution yields the total volume.
The volumes were measured without the aminoglycoside inside the binding site.
PCA was done with the use of bio3d package177 for R. Adaptive Poisson-Boltzmann
Solver (APBS)178 was used to calculate the ESP of the X-ray structures of AME ternary com-
plexes (enzyme:cofactor:aminoglycoside). However, for the calculations, we deleted the
aminoglycoside that was in the X-ray structure. Next, the Surface Diver software179 was
used to compare these potentials in relation to an aminoglycoside core (i.e., neamine part)
inside the binding cleft. Surface Diver performs a decomposition of ESP into spherical har-
monics, and therefore, the compared molecules do not need to be structurally or sequence
related.
The binding free energy and its per-residue decomposition was computed by MMPBSA.py,
a part of AmberTools, on total of 3333 frames from each trajectory, i.e., every 6 ps. For calcu-
lating the electrostatic interactions, we chose the simpler generalized Born model132 instead
of the Poisson-Boltzmann model180 because of the large sizes of simulated systems and large
56 PARAMETERIZATION AND PREPARATION OF THE SIMULATED SYSTEMS
number of simulations. The calculated energy accounts only for the enthalpic part of the to-
tal binding free energy (Ecalc  H; see Chapter 2, Section 2.8 Assessment of the binding free
energy), and therefore we used the calculated values only to compare the contributions com-
ing from single residues. Moreover, the experimental data on the free energy of binding of
aminoglycosides to AMEs is scarce, thus we could not relate to them the calculated energy
values.
In the AAC_HOLO and APH_HOLO simulations, some water molecules close to kana-
mycin A atoms were especially stable (calculated –factors were less than 30 Å2), thus we
decided to include them as part of the receptor when calculating the energies. However, in
each of the three separate APH_HOLO simulations, these were different water molecules.
Therefore, we performed three separate calculations for each APH_HOLO simulation and
then we combined the results using the weighted mean () and the unbiased error estima-
tion (ff ):
 =
Ni=1wixi
V1
;
ff2 =
V1
V 21   V2
N∑
i=1
wi(xi   
)2 ;
where wi is the weight of element xi (here the weights are reciprocals of standard errors of
energy values calculated for each of the simulations); N = 3 is the number of simulations;
V1 = iwi and V2 = iw2i .
To determine which residues are contributing the most to kanamycin A binding to
AMEs, we used a measure introduced in Ref.181 The amino acid efficiency is defined as
follows:
EFF =
Eres
Nhvy
;
where Eres is a total contribution of a residue (difference of the MMGBSA energy for the
residue in the APO and HOLO states), and Nhvy is a number of heavy atoms in this residue.
Chapter 4
Results and discussion
We used several tools of theoretical biophysics to investigate the binding sites of amino-
glycosides located in different biomolecules: the ribosomal RNA A-site and three AME rep-
resentatives. We focused on two types of bacterial resistance: (i) mutations in the RNA bind-
ing site; and (ii) modification of aminoglycosides by the bacterial enzymes. We analyzed the
“static” X-ray structures but the most important conclusions are based on the results from
molecular dynamics simulations of these different molecules and their complexes with two
aminoglycoside representatives, kanamycin A and paromomycin. This wide range of struc-
tures and the biochemical differences between them, required the usage of various methods.
We also developed a new method for conformational analysis. In this study, we aimed at
characterizing and comparing the environments that these biomolecules provide and the
types of interactions formed with aminoglycosides.
This chapter is organized as follows. First, we present our new tool for analyzing in-
ternal dynamics of biomolecules, and we demonstrate its usability through a series of tests
in Section 4.1 New method for identifying similarly moving atoms in molecular conformation sets.
Next, in Section 4.2 Bacterial resistance mechanism 1: ribosomal RNA A-site mutations, we de-
scribe and discuss the results from the MD simulations of the mutated A-site models. Fi-
nally, Section 4.3 Bacterial resistance mechanism 2: enzymatic aminoglycoside modification focuses
on the MD simulations of AMEs, where the results are explained and discussed.
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4.1 New method for identifying similarly moving atoms
in molecular conformation sets
Currently, the simulations produce even hundreds of thousands of molecular confor-
mations that have to be carefully analyzed. Especially in classical MD, these conformations
are most of the time very similar to one another, due to the intrinsic limitation of sampling
restricted to only a couple of local energetical minima. Therefore, noticing a larger transition
can be difficult. To make it easier, one often decreases the dimensionality of the description
of molecular motion. One of the methods is searching for similarity in atomic motions. The
classical approach involves calculation of cross-correlation coefficients, which yield DCCM.
This approach, however, has some limitations, as explained in Chapter 2, Section 2.5.3 Corre-
lated motions. Therefore, we proposed an alternative method, where the molecule is divided
into so-called “dynamic domains”, based on its conformations. These dynamic domains
can be defined as parts of the molecule that stay internally rigid but move in relation to one
another. The idea is not new — the first algorithm and software, Hingefind, was proposed
by W. Wriggers and K. Schulten in 1997.182 Their algorithm compares two conformations of
a protein by least-square fitting, and then finds the stable fragments and defines a rotation
axis. DomainFinder, designed by Konrad Hinsen,183, 184 is perhaps more commonly used.
Based on a normal mode analysis, DomainFinder finds the directions of harmonic motions
of atoms around their energetic minimum.136 find.core from the R package bio3d,177 finds
the atoms that are invariant in a molecule, based on its conformations or alignment to a sim-
ilar set of structures. FindCore algorithm185 analyzes variation of distances between pairs
of atoms and also outputs the “core atoms”, i.e., the atoms that change their positions the
least. It does not, however, predict a clear division into dynamic domains. The CYRANGE
program186 gives this division explicitly, but it was optimized to analyze the data from NMR
experiments, not MD simulations. Next, the DynDom database187, 188 calculates and stores
a division into dynamic domains for proteins that have two experimentally resolved con-
formations. A more recent server, PiSQRD,189, 190 uses a covariance matrix to extract low-
energy modes of motions, and, based on these modes, the atoms are grouped into dynamic
domains.
The presented list of software and methods shows that a lot has been already done
to analyze the internal dynamics of molecules. However, none of these approaches was
designed to deal with large datasets that come from simulations — they focus on experi-
mentally resolved conformations. Moreover, all of the mentioned software analyzes only
proteins. Therefore, we found a need to create a similar tool that would deal well with data
produced by simulations and that could be also applied for nucleic acids. Additionally, we
wanted to improve the way of detecting the correlations of motions and find a method that
does not depend on the order of conformations and the type of molecules being analyzed.
Below, we describe our new algorithm, the implementation (Geometrically Stable Sub-
structures, GeoStaS) and its testing on experimental data (obtained from NMR) and MD
simulations, of proteins, nucleic acids and their complexes. The software is open source and
freely available for download: http://bitbucket.org/jrom/geostas or
http://bionano.icm.edu.pl/Software/GeoStaS.
4.1.1 GeoStaS algorithm
The workflow of GeoStaS algorithm is presented in Figure 4.1. The algorithm is based
on finding similar atomic motions. Instead of concentrating on the whole molecule, we
extract trajectories of individual atoms from the provided set of molecular conformations
(which can be a trajectory from a simulation or an ensemble of experimentally resolved
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Figure 4.1: Schematic representation of the workflow in the GeoStaS algorithm. Detailed descrip-
tion is given in the main text.
structures). These traces of atomic movements are then compared strictly geometrically,
through finding an isometry, i.e., translation plus rotation, that would minimize the distance
between them. To find such translation, the conformations are first repositioned with regard
to coordinates of the first conformation. Finding the best rotation is more complicated. In
order to simplify the calculations, this is done in the quaternion space.
Rotation in quaternion space
Quaternions are an extension to complex numbers, introduced by sir William Rowan
Hamilton in the 19th century.191 A quaternion is defined as a four tuple:
q = q0 + ~q = q0 + q1 ~i+ q2  ~j + q3  ~k ; (4.1)
where q0 is named the scalar part and ~q is the vector part. Multiplication of quaternions is
non-commutative and it is defined by two rules:
~i2 = ~j2 = ~k2 =  1 ;
~i ~j ~k =  1 :
Then, multiplying two quaternions, p and q, gives:
(p0 + ~p)(q0 + ~q) = p0q0   ~p  ~q+ p0~q+ q0~p+ ~p ~q :
The conjugate of a q is q = q0   ~q , and their multiplication:
qq = q20 + q
2
1 + q
2
2 + q
2
3
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gives a nonnegative real number.192
In the case of GeoStaS algorithm, the key feature of quaternions is that when construct-
ing a quaternionic operator and applying it to a vector ~v in R3, we obtain the rotated vector
~v 0 by angle  :
~v 0 = q ~v q 1 ; (4.2)
q = cos(=2) + ~a  sin(=2) ; (4.3)
where ~a is the direction of ~q, i.e., the normalized vector part of q; and q 1 = q=jqj2.
The standard approach for performing a rotation in Cartesian space uses a rotation
matrix 3  3 that contains trigonometric functions of rotation angle, which are difficult to
implement. In the quaternion space, one needs only four parameters (one quaternion) and
there are no trigonometric functions. Kneller et al.193 have presented an elegant way of
implementing this search for the best rotation in quaternion space. It can be reduced to a
simple eigenproblem:
M^  q =  q ; (4.4)
where q is the quaternion that describes the rotation; and  is a diagonal matrix. Matrix M^
is of the following form:193
M^ =
N∑
k=1
[(
~xi(k)  ~xj (k)
)2
~uij (k)
T
~uij (k) P^ij (k)
]
;
~uij (k) = ~xi(k) ~xj (k) ;
P^ij (k) = ~xi(k)  ~xj (k)
T + ~xi(k)
T  ~xj (k) ;
where ~xi(k) and ~xj (k) describe the positions of the two atoms, i and j , respectively, in the
conformation k ; and T denotes the transpose of a matrix. For each pair of atoms, their traces
are compared, yielding a separate eigenproblem of the form as in Equation 4.4.
The result is a set of four eigenvalues, where the largest value, 1, points to the best rota-
tion, while the smallest value, 4, shows the worst one. Kneller et al. have shown that with
the smallest eigenvalue one gets also the normalized distance between the two compared
objects:193

 =
(
M11
4
) 1
2
: (4.5)
The distance 
 2 [0; 1], which discriminates between the parallel (
  0) or anti-parallel
order (
  1). Since in our algorithm, we want to find the atoms that move in the same
direction at the same time (i.e., that are correlated and not anti-correlated), we define a sim-
ilarity coefficient as: SC = 1  
, so that higher values would describe better correlations.
Clustering of similarity matrix
These similarity coefficients are calculated per each pair of atomic trajectories and a so-
called atomic movement similarity matrix (AMSM) is constructed (see Figure 4.1). Next, this
matrix has to be clustered into groups with maximal internal similarity. For this purpose, a
modified nearest-neighbor graph algorithm194 is used. The atoms are represented as nodes
of the graph. Edges, weighted with similarity coefficients (wij  SCij ), connect each two
atoms that are farther than four residues apart at a sequence level. The similarity coefficients
for atoms closer than this limit are naturally very close to 1, thus including these values
would bias the outcome of clustering and would not provide significant results. Atoms
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(nodes) connected by an edge are called neighbors. If additionally the weight wij of this edge
is larger than a given wmin = wmax   w (we call w the threshold), these atoms are called
the nearest neighbors.
Scheme of the nearest-neighbor algorithm:
1. within not yet assigned edges find the edge Vmax with maximal weight, wmax ;
2. take the nodes, a and b, that are connected by Vmax and create a new cluster C ;
3. expand the cluster:
(a) from not yet assigned neighbors of a or b take each node that has minimum ncomm
common nearest neighbors with any gc 2 C ;
(b) stop when no more neighbors of a or b pass this criterion or there are no more
nodes left;
4. repeat from 1 until all nodes are assigned to clusters.
After a series of tests, the value of ncomm was set to 80% of the number of the nearest
neighbors of gc 2 C . The threshold, w , is a parameter, adjustable by the user, since it
defines the “coarseness” of clustering, and the user has to decide on a more or less detailed
division.
Apart from the nearest neighbor algorithm, we also tested a simple hierarchical merg-
ing approach. This clustering is performed on the columns of AMSM, not on separate val-
ues of the similarity coefficients. In the beginning, each column represents one cluster. In
every step of the hierarchical clustering, the two clusters that have the minimal distance
are merged. The distance is calculated as a vector difference between the average vectors
(columns) of each cluster. However, this type of clustering requires a number of domains to
be given as an input. There are some methods to help decide when the clustering is optimal
(see e.g., Ref.173), and we plan to implement one of them in the nearest future. Although
the hierarchical merging clustering algorithm seems promising, we have not fully tested
it, and therefore we present only the results obtained with the use of the nearest neighbor
clustering.
Automatic mode
The GeoStaS has an automated mode that suggests an optimal division into dynamic
domains. In this mode, an output is generated for a set of threshold values (w : 0.3, 0.25, 0.2,
0.15 and 0.1) and the associated divisions of the biomolecule are compared. The comparison
is based on the RMSD of each of the identified domains:
Rdivision =
1
Nres
∑
D
〈√
1
N

∑
i
∣∣~xi(k)   ~xi(k=0)∣∣2 〉
K
; (4.6)
whereNres andN are the numbers of all residues and all atoms in the molecule, respectively;
D = fdjg are the domains that have more than two residues; i traverses all the atoms in the
domain dj ; ~xi(k) describes the position of atom i in the conformation k ; and h iK denotes
an average over the set of conformations K = fkg. The minimal value of Rdivision gives the
optimal solution. This can be then used as a starting point for a more detailed analysis.
Implementation
We chose the Java programming language, because it enables easy implementation of
the graphical interface, easy development, and it is independent of the operating system.
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GeoStaS processes either the text file (in the PDB format — version 3.3 or the binary file
(in the DCD format, used e.g., by the popular MD softwares NAMD149 or CHARMM195).
The conformations are superimposed onto the first one, in order to remove the rotation and
translation of the molecule as a whole. The user has to choose between the automatic and
manual mode, and whether to consider only the C atoms (or phosphorus in case of nucleic
acids) or three atoms per residue (i.e., C-C-N for proteins and P-C30-C40 for nucleic acids).
There are two types of output: the raw AMSM and the PDB file with the molecule divided
into dynamic domains.
4.1.2 Tests on experimental and computational data
The tests were performed on more than 30 conformation sets from NMR experiments
and on several trajectories from MD simulations. The results showed that GeoStaS is capa-
ble of correctly identifying dynamic domains in different structures: proteins, nucleic acids
and their complexes. This is a unique feature of GeoStaS, since all of the already available
software accepted only protein structures as an input. Moreover, none of the other programs
is able to efficiently handle large data files such as trajectories from molecular simulations.
Figure 4.2: Visualization of the results obtained from GeoStaS, for the NMR ensemble 1D1D:
(A) the atomic movement similarity matrix (AMSM), the color bars in the bottom depict which
residues are assigned to different domains; (B) one molecular conformation colored according to
the dynamic domains found by GeoStaS, (C) the whole NMR ensemble superimposed on the blue
domain.
Experimental data
Exemplary results are presented in Figure 4.2: AMSM, and the molecule colored ac-
cording to the predicted dynamic domains. The presented molecule is a Rous sarcoma virus
capsid protein (PDB id 1D1D).196 Based on the 20 NMR conformations of this molecule,
GeoStaS found four domains. This agrees with the analysis of the NOE signals,196 which
identifies the N-terminal (red and blue fragments in Figure 4.2B) and C-terminal (orange
fragment) domains as moving independently. Moreover, according to the experiment, one
linker between the helices (indicated by the red arrow in Figure 4.2B) is similarly flexible as
the linker between the domains (gray arrow). Thus, the movements of the helices connected
with this red-colored linker could differ from the movement of the rest of the N-terminal
fragment.
The outcome of the analysis of the experimental data was compared with the most re-
cent program, CYRANGE.186 Figure 4.3 presents the domains found by GeoStaS with the
www.wwpdb.org/documentation/format33/v3.3.html
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Figure 4.3: The optimal divisions for all tested NMR ensembles for (left) one– (C or P) or (right)
three– (C-C-N or P-C30-C40) atoms-per-residue representation; each dynamic domain is colored
differently. The NMR ensembles are identified by their PDB codes with the number of conformations
given in brackets. The numbers on the far right and left sides show the minimal Rdivision for each of
the ensembles. For comparison, the divisions obtained with the CYRANGE program are displayed
as black lines below every color bar. CYRANGE gives a range of residues that belong to each domain,
and these can have gaps; here, different domains, if identified, are marked with different line widths;
the lines for the three-atoms-per-residue mode are scaled by a factor of three, to match the scale of
the colored bars, since CYRANGE has only the C mode. The structures that were not tested in
Ref.186 are marked with an asterisk. The structures containing nucleic acids, which CYRANGE does
not process, could not be compared; these are: 1EKZ (protein/RNA complex), 1A60 and 1P5M (both
containing RNA).
automatic mode, in relation to the core atoms found by CYRANGE. In general, the do-
mains identified by GeoStaS that had the smallest Rdivision were similar to the ones found
by CYRANGE, but in some cases there were discrepancies. GeoStaS found too many do-
mains for very small NMR ensembles (up to 12 conformations) of structures having flexible
loops or termini. One such case is depicted and described in Figure 4.4. This unreasonable
division produced by GeoStaS is most likely caused by not enough data in the ensemble
for our algorithm, which is optimized for a larger number of input conformations. As can
be seen from Equation 4.6, the Rdivision value is based on averaging, thus the more data is
provided, the more precise the division. Overall, for proteins GeoStaS showed a similar do-
main division as the CYRANGE software and the smaller value of Rdivision pointed to a more
reasonable division.
For the tests on experimental data of nucleic acids, we chose several ensembles that had
more than 20 conformations. The results of the analysis of two ensembles are presented in
Figure 4.5. The ensemble 1P5M197 contains 36 conformations of the HCV IRES domain IIa —
a non-canonical RNA helix with a large internal loop region, formed by five bases (A53, A54,
C55, U56 and A57). The division found by GeoStaS shows that the loop and the flanking
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helical regions were identified as separate domains (Figure 4.5A–C). This agrees with the
experimental analysis, which demonstrated that the whole structure was bending in relation
to the loop region.197 Another ensemble, 1EKZ,198 is a complex of a double stranded RNA
with a double-stranded RNA-binding domain from an E. coli protein. The visualization of
the GeoStaS analysis, shown in Figure 4.5D–E, illustrates that only a small part of the protein
“moved along” with RNA (grey domain), so as to maintain the hydrogen bonds that were
shown to contribute the most to a stable complex.198
Figure 4.4: NMR ensembles with few conformations can be problematic for GeoStaS, if they rep-
resent a very flexible molecule. The optimal division seems too complicated (A) but when setting
the threshold to a higher value, a more reasonable division intro dynamic domains is obtained (B).
Another NMR ensemble that has few conformations was not as problematic (C) because the confor-
mations did not differ much from each other.
Figure 4.5: NMR ensembles containing nucleic acids, colored by the domains recognized by
GeoStaS (C/P representation, automatic mode). (A–C) RNA non-canonical helix: (A) one con-
formation with the loop-forming bases marked as black sticks, and all NMR conformations superim-
posed with respect to the red (B) or blue (C) domain. (D–E) Protein:RNA complex: (D) all conforma-
tions superimposed with respect to the grey domain, (E) two chosen conformations illustrating how
the protein “follows” the nucleic helix. Amino acids whose mutations resulted in abolishing of RNA
binding198 are shown as sticks.
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Simulations
We aimed at facilitating the analysis of conformational changes in biomolecular simula-
tions, and therefore the main tests were conducted on various trajectories obtained from MD
simulations. The first test was performed on the simulation of a GroEL chaperone monomer
complexed with ATP (Figure 4.6).199 The chaperonin GroEL is a large oligomeric protein
(ca. 800 kDa) that helps fold non-native proteins in E. coli.200 After forming a complex with
the co-chaperonin GroES, it provides a protective chamber, where the substrate proteins re-
gain their functional shape. During this complexation the subunits of GroEL undergo large
conformational changes, which have been extensively characterized.199, 201, 202
This analysis required using GeoStaS in the manual mode, probably due to the large
size of the system and the complexity of the movements. However, setting the threshold
to 0.05 gave an interesting division into dynamic domains, as presented in Figure 4.6B–C.
Structural studies divide the GroEL monomer into three domains:201 equatorial, interme-
diate, and apical, as illustrated in Figure 4.6A. The division found by GeoStaS resembles
these structural domains, however, the apical and equatorial domains were subdivided into
smaller dynamic domains: yellow and gold fragments in the apical part, and blue, grey and
red in the equatorial part. The yellow-colored dynamic domain contains helices K and L,
which stay close to each other during the elevation of the apical domain while forming the
chamber in the GroEL chaperone. Therefore, their movements should be slightly different
than the movement of the rest of the apical domain. Moreover, the red-colored part of the
equatorial domain consists of helices that interact with the bound ATP, which again would
cause their movements to differ from the rest of the equatorial domain. This is again in
good agreement with previous structural studies highlighting the internal motions in the
equatorial domain upon ATP binding.199, 203
We compared the similarity coefficients from our AMSM with the standard DCCM val-
ues and we found some discrepancies. Figure 4.7 highlights some areas that differ between
these matrices. For example, AMSM showed correlations of motions of helices A, B and C
with helix M and their anti-correlations with helices K and L, contrary to the DCCM analy-
sis (area 1 in Figure 4.7). The four former helices (A, B and C from the equatorial domain,
and M from the intermediate domain) move in the same direction during the first stage of
conformational changes in the GroEL cycle,202 while helices K and L, situated in the apical
domain, move in an opposite direction during this transition. Therefore, the relations found
by AMSM seem reasonable. Moreover, helices F and G were anti-correlated with helices Q
and R in DCCM, in contrast to AMSM (area 2). It has been shown that first, helices F and G
(from the apical domain) approach the equatorial domain (thus also helices Q and R), in
order for the apical domain to move upwards and then to a fully opened conformation.202
Similar case is between helices N, O and helix F (area 3). Again, the relation found by AMSM
seems justified.
Another test of a protein simulation was conducted on the trajectory of a bacterial elon-
gation factor, EF-Tu204 (Figure 4.8). This protein complexates with GTP, and subsequently
with aminoacylated tRNA, to deliver it to the ribosome. Next, thanks to the energy that
comes from the GTP!GDP hydrolysis, the tRNA is released and the EF-Tu:GDP complex
dissociates from the ribosome. Both, the experimental205–207 and computational studies204
showed that some parts of the protein were significantly more dynamic when GDP was
bound than without the nucleotide diphosphate — these fragments are termed switch I
and II. Our analysis correctly identified switch I as a distinct domain (colored orange in
Figure 4.8B). In addition, the majority of switch II residues were assigned to a fragment of
the red domain, which suggests that its movements differed from the movements of the
neighboring residues, which were in the gray domain.
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Figure 4.6: Division into structural and dynamic domains of the GroEL monomer. (A) A cartoon
model of the monomer with marked helices and structural domains. (B–C) Visualization of the do-
mains found by GeoStaS for the threshold (w) set to 0.05 — several trajectory conformations are
superimposed relative to the domains colored: (B) grey, and (C) gold.
Figure 4.7: Analysis of the correlation patterns in the GroEL monomer — (A) DCCM versus
(B) AMSM; some of the areas that differ are marked by the red and black squares and discussed
in the text; the meaning of the color scales is the same in both matrices: dark blue shows strong anti-
correlations, and yellow — strong correlations. Above the AMSM, the color bars represent different
dynamic domains (coloring is the same as in Figure 4.6B–C). The letters to the right of DCCM mark
the GroEL helices shown in Figure 4.6A.
We compared the AMSM and DCCM values for the EF-Tu:GDP simulation, and ad-
ditionally, we applied the clustering algorithm to both matrices, in order to compare also
the resulting divisions into dynamic domains (Figure 4.9). Again, we noticed differences
between these matrices. For example, the area marked 1 in Figure 4.9 shows the relation
between movements of switch I and domain II of EF-Tu (see Figure 4.8A), which was identi-
fied as correlation by DCCM and anti-correlation by AMSM. Moreover, the DCCM-derived
dynamic domain colored blue contained switch I together with domains II and III. As de-
scribed above, switch I was found to be much more mobile than the rest of the protein,
therefore the AMSM result seems more reasonable. The relation between the movement
of a fragment of domain I and domain III is enclosed in the area marked 2. The original
analysis of the simulation204 showed that domain I moved away from domain III, and the
anti-correlation found by AMSM agrees with this observation. Finally, the area number 3,
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Figure 4.8: Division into dy-
namic domains of (A) EF-Tu
(first trajectory frame) and
(B) EF-Tu:GDP complex (last
trajectory frame; ligand is not
shown for clarity). Each struc-
ture is colored independently.
Structural domains are encircled
and numbered in panel (A).
Residues that form switch I are
depicted as sticks and colored
black in both panels; in panel (B)
also switch II is marked, colored
green.
Figure 4.9: Analysis of the correlation patterns in the EF-Tu:GDP complex — (A) DCCM versus
(B) AMSM; some of the areas that differ are marked by the red and black squares and discussed in
the text; the meaning of the color scales is the same in both matrices: dark blue shows strong anti-
correlations, and yellow — strong correlations. Below the matrices, the color bars represent different
dynamic domains (the coloring below AMSM is the same as in Figure 4.8B).
according to AMSM, points to a correlation between the movement of domains II and III,
but according to DCCM this movement was anti-correlated. Additionally, DCCM-derived
division into dynamic domains classifies domain III to a different dynamic domain than the
majority of domain II (yellow and blue, respectively). Again, the AMSM result is in ac-
cord with the original analysis, where the researchers reported that these fragments did not
recede.204
Next, we performed tests on systems containing nucleic acids: trajectories of an elbow
segment of helix 38 (H38) of 23S ribosomal RNA from Haloarcula marismortui208 and of bac-
terial elongation factor EF-Tu complexed with tRNA.204
As mentioned above, EF-Tu, complexates with tRNA to deliver it to the ribosome dur-
ing the translation process. The shape of this complex highly resembles the shape of another
factor also involved in the peptide elongation process of bacterial translation, EF-G. These
two structures are presented in Figure 4.10. Apart from the shape, the motions and also their
binding sites on the ribosome are similar. Structurally, EF-G was divided into five domains
(Figure 4.10A), but dynamically, only two domains were found by GeoStaS (Figure 4.10B–
C). The red-colored domain constitutes a core formed of structural domains: I, II, III, and V.
The G0 insertion, which is exclusive for EF-G, was classified as a separate dynamic domain
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(colored blue) together with the flexible, solvent-exposed fragments. Almost the entire do-
main IV was assigned to this blue domain, which is reasonable because this domain bends
upon binding of EF-G to the ribosome.
The division of the EF-Tu:tRNA complex is presented in Figures 4.10E–F. According to
the GeoStaS analysis, the anticodon arm of tRNA was moving separately, while the accep-
tor stem together with the EF-Tu protein formed one dynamic domain (colored red). This
resembles slightly the division of EF-G.
Figure 4.10: Comparison between the structural (panels A and D) and dynamic domains (panels
B–C and E–F) for the EF-G protein and the protein:RNA complex — EF-Tu:tRNA. In panels (C) and
(F) several conformations from MD simulations are superimposed relative to the red domain. The di-
vision of EF-G was calculated for the C representation (automatic mode), while for the EF-Tu:tRNA
the presented division was for the three-atoms-per-residue representation (automatic mode).
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Figure 4.11: Division into dynamic domains found by GeoStaS for the simulation of H38 frag-
ment. (A) Initial structure of the H38 kink-turn region; the backbone is colored according to the
optimal division into dynamic domains found by GeoStaS with the one-atom-per-residue represen-
tation. Snapshots from the simulation are superimposed with regard to the domain colored (B) red
or (C) orange, to emphasize the movements observed in the trajectory.
The last case presented here is the analysis of the simulation of a H38 RNA fragment
from the bacterial ribosome.208 This RNA fragment forms a kink-turn motif, which is com-
monly found in ribosomal RNA structures. The kink-turns are very dynamic, often initiating
large conformational changes.209 The dynamic domains found by GeoStaS show exactly this
high flexibility, as visualized in Figure 4.11. The H38 kink-turn fragment is divided into four
parts, which emphasizes two types of motion: the bending mode, which changes the angle
between the flanking helices, and the breathing mode of the helical parts. The same conclu-
sions were drawn in the original paper,208 albeit only after many measurements of distances
and angles between the two strands. Our analysis simplifies this process.
4.1.3 Summary
We have presented an algorithm, GeoStaS, for dividing a molecule into dynamic do-
mains based on its conformations. The novelty of this algorithm is its focus on geometric
comparison of the atom traces, which enables analysis of any set of conformations, regard-
less of their order. Additionally, this approach properly recognizes all types of movement
similarities, including rotational correlations. The algorithm was implemented in a graph-
ical software, which has a minimal number of parameters and automatically suggests an
optimal solution. We have shown that with GeoStaS the analysis of internal molecular mo-
tions can be simple. The software deals well with large datasets from simulations of various
biomolecules, including proteins, nucleic acids and their complexes. The resulting division
into dynamic domains helps describe the changes between subsequent conformations. We
showed that GeoStaS is able to identify the correlated vs. anti-correlated motions better than
the standard cross-correlation matrix, because of accounting also for rotational correlations.
The algorithm presented here is generic because it can deal with any objects that are
comparable through geometric transformations. Therefore, not only conformations of one
molecule can be analyzed but also, for example, conformations of its mutated variants.
Moreover, the outcome of the analysis can have different applications, such as for gener-
ating different conformations for flexible docking procedures or fitting a model into low
resolution microscopy maps.
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4.2 Bacterial resistance mechanism 1: ribosomal RNA A-site
mutations
The two following sections describe the part of the research that focused on the two
bacterial resistance mechanisms, namely the modifications of bases in the primary amino-
glycoside binding site, the 16S rRNA A-site, and the production of the enzymes that chemi-
cally alter aminoglycosides. First, we describe the results from our simulations of the A-site
models with different mutations, with and without paromomycin.
4.2.1 Conformations of bound paromomycin
To investigate the conformations that paromomycin adopts when bound to the mutated
A-site, we calculated the ffi= dihedral angles of paromomycin’s linkages, as described in
Section 3.3.2 Parameterization validation. Figure 4.12 presents the ffi= conformations of par-
omomycin in different A-site models. In the WT A-site, paromomycin adopted a conforma-
tion that was also the most frequently sampled one in solution (compare Figure 4.12, top,
with Figure 3.4E–G). Moreover, this conformation did not change when paromomycin com-
plexated with the mutated RNA structures. Upon binding to different rRNA molecules,
the mobility of all three linkages of paromomycin was only restrained to the region most
populated in water. The most flexible part of paromomycin was the ring IV, which pro-
trudes from the A-site. Only in the G1491A and U1406C/U1495A simulations, this ring was
slightly more mobile than in the other simulations of the complexes.
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Figure 4.12: Conformations of paromomycin bound to different RNA receptors. On the left, the
most populated conformations from the simulations are presented. The graphs depict changes of the
dihedral angles of the linkages between the rings.
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4.2.2 Internal dynamics of the bare ribosomal RNA A-site
To check the mobility and stability of the simulated RNA models, first, we looked at
some basic measures, i.e., RMSD of the atomic positions from the initial conformation and
RMSF of each residue. In all simulations, RMSD of the RNA A-site was leveled and the
average did not exceed 2.9 Å (Table 4.1). These measures revealed an overall stabilization
of the A-site upon aminoglycoside binding, although at a substantially smaller level in the
simulation of the doubly-mutated A-site, i.e., U1406C/U1495A vs. U1406C/U1495A_PAR.
This was also visible in the range of RMSF values, as shown in Figure 4.13. In the WT_PAR
simulation, there was a shift towards smaller values compared to WT. Such a trend was also
observed in the simulations where G1491 was mutated. On the contrary, for the simulations
where the U1406U1495 pair was mutated, the histograms overlap. These findings are in
agreement with the results from previous simulations of different aminoglycosides bound
to RNA, which showed that the WT complexes were more stable than the free A-site.85, 86
Table 4.1: Average RMSD and ligand RMSF for the RNA simulations
avg RMSD [Å](a) ligand RMSF [Å]
simulation name part A part B part A part B
WT(b) 1.560.26 2.350.39 — —
WT_PAR 1.300.22 1.410.17 0.86 0.74
WT_KAN 1.690.28 1.860.23 1.10 1.10
G1491A 2.650.34 2.720.45 — —
G1491A_PAR 1.710.36 1.710.18 2.37 0.70
G1491U 2.690.42 2.830.46 — —
G1491U_PAR 1.370.21 1.510.20 0.97 0.86
U1495C 2.380.24 2.710.34 — —
U1495C_PAR 1.790.23 1.910.30 2.09 1.14
U1406C/U1495A 2.420.27 2.150.40 — —
U1406C/U1495A_PAR 2.180.60 1.600.23 3.00 1.59
(a) Average values shown with the standard deviation, calculated for
all heavy atoms in each of the symmetrical parts of the model,
labeled A and B (see Figure 3.1);
(b) Data taken from our previous study.85
Bacterial resistance mechanism 1: ribosomal RNA A-site mutations 73
Fi
gu
re
4.
13
:H
is
to
gr
am
s
of
pe
r-
re
si
du
e
R
M
SF
va
lu
es
[Å
]i
n
th
e
M
D
si
m
ul
at
io
ns
of
th
e
A
-s
it
e
m
od
el
s.
Ea
ch
co
lu
m
n
sh
ow
s
va
lu
es
fo
r
di
ff
er
en
ts
im
ul
at
io
ns
(W
T
an
d
th
e
st
ud
ie
d
m
ut
an
ts
,w
it
h
an
d
w
it
ho
ut
pa
ro
m
om
yc
in
),
an
d
th
e
tw
o
ro
w
s
de
pi
ct
va
lu
es
fo
r
th
e
tw
o
sy
m
m
et
ri
ca
lp
ar
ts
of
th
e
A
-s
it
e
m
od
el
.
74 RESULTS AND DISCUSSION
Monitoring hydrogen bonds in base pairs
To investigate the source of the observed differences in the RMSF ranges (Figure 4.13),
we monitored each of the bases and base pairs in the simulations of the mutated structures
without paromomycin. Figure 4.14 depicts the number of hydrogen bonds formed within
each base pair for three simulations: WT, G1491A, and U1406C/U1495A. We found that
some base pairs were unstable in the simulations G1491A, G1491U, and U1406C/U1495A.
Specifically, it appears that the double mutation did not provide enough stability for the
newly formed 1406C:1495A base pair, while the mutations of G1491 were causing disrup-
tion of its pairing with the opposite RNA strand. In addition, we noticed that the bulged
adenines, A1492 and A1493, formed hydrogen bonds with the opposite A1408 more often
in the structures with mutated base G1491 than in the remaining ones. These observations
are discussed in details below.
Figure 4.14: The number of hydrogen bonds in base pairs versus simulation time for selected
simulations. The base pairs with mutated bases are marked red and the number of hydrogen bonds
is depicted in grayscale code.
Stability of the U1406U1495 pair is disrupted upon mutations
Previous studies have suggested that the stability of the U1406U1495 base pair influ-
ences the stability of the entire A-site.45, 84 Our simulations suggest that the double mutation
(U1406C/U1495A) significantly interfered with the stability of this base pair. In the X-ray
structure of the WT A-site (1J7T), the UU pair is formed by two hydrogen bonds, which was
also reproduced in our WT simulation, as shown in Figure 4.14A. In the doubly-mutated A-
site, the resulting C:A pair shared maximally one hydrogen bond (Figure 4.14C). The struc-
tures with neither of the uridines mutated preserved the wild type-like geometry of the
U1406U1495 pair with two hydrogen bonds, as presented in Figure 4.14B for the G1491A
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Figure 4.15: Conformations of the
U1406U1495 pair and its mutated al-
ternatives observed in the simulations
of the bare A-site models. The distri-
bution of charges changed upon mu-
tations — negatively charged moieties
are marked with red circles, positively
charged ones are marked with blue
squares. [Figure taken from our published re-
sults211]
simulation. In the U1495C structure, the resulting base pair (U1406:1495C) was formed with
two or even three hydrogen bonds (data not shown). In summary, bases 1406 and 1495
formed a pair for the majority of the simulation time in all simulations (Table 4.2); however,
the geometry and hydrogen bonding strength of this pair varied. Figure 4.15 compares the
different base pairing observed for U1406U1495 in the WT and mutated structures. In the
WT simulation, the U1406U1495 base pair adopted a stable conformation with two hydro-
gen bonds (Figure 4.15A). The double mutation (U1406C/U1495A) resulted in a less stable
C:A pair, which often adopted an experimentally observed conformationy (Figure 4.15B).
However, sometimes the mutated 1406C base rotated to an almost perpendicular position
relative to the other base (Figure 4.15C), which indicates a weak hydrogen bonding. We did
not observe such a behavior in any other simulation. For the majority of the U1495C sim-
ulation time, the conformation of the U:C pair resembled a well-known 4-carbonyl-amino
pattern127 (also called cis W.C./W.C.;210 depicted in Figure 4.15D). Sometimes a different
hydrogen bonding pattern occurred, as illustrated in Figure 4.15E.
In the U1406C/U1495A structure, upon the change of base 1495 from a smaller pyrim-
idine (uracil) to a larger purine (adenine), the shape of the base pair was disrupted and
during the simulation the adenine was situated more towards the aminoglycoside binding
site than the uracil in the wild type structure. This change in the 1406C1495A pair geometry
may hinder paromomycin binding through steric clashes. However, it did not influence the
overall stability of the A-site model, which is in agreement with previous study.34 Only the
mobility of the A1492 and A1493 has been affected, as discussed below.
Importantly, also the charge distribution was altered upon mutations within the
U1406U1495 pair, as can be seen in Figure 4.15. In the WT structure, these two uracils pro-
vide negatively charged C=O moieties that form hydrogen bonds with aminoglycosides.
The double mutation deletes this negative potential completely, while the U1495C substitu-
tion provides only one of the original moieties. Therefore, even if the geometry of the base
pair was not altered, the change in the charge distribution could hinder forming of hydrogen
bonds with an aminoglycoside binding to this site.
yAs reported in the Database of RNA base pair structures: http://bps.rutgers.edu/atlas/bppattern/ac_5
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Substitutions of base G1491 cause a shift in base-pairing
Another disruption in base pairing pattern involves G1491 in the simulations where it
was mutated to either 1491A or 1491U. Table 4.2 compares the duration of base pair form-
ing for the relevant simulations. During the WT simulation, the G1491:C1409 base pair was
stable, forming three hydrogen bonds in both parts of the structure almost throughout the
simulation time (see Figure 4.14A). Introducing the mutation resulted in a poorly bound
pair throughout the G1491A simulation, as was shown in Figure 4.14B, and even less stable
in G1491U. The visualization of trajectories showed a shift in the base pairing pattern (Fig-
ure 4.16), where some bases were in the flipped out position (1491A in Figure 4.16B or C1409
and A1410 in Figure 4.16C). Due to the intrinsic flexibility of RNA such changes occur rel-
atively often212 and we observed a similar shift in our previous study.85 Results presented
herein suggest that the different base pair pattern resulted in a change of the binding cleft’s
shape (described below).
Table 4.2: Base pairing in the RNA simulations
duration of pairing [%]
base pairs # G1491A G1491U U1495C U1406C/U1495A WT(a)
1406 :(b) 1495(c) 100 99 98 99 81 84 89 90 96 97
A1408 : A1492 6 1 4 2 0 15 2 0 0 9
A1493 49 36 47 25 6 24 0 0 50 25
C1409 : 1491(d) 29 34 16 21 not applicable 100 100
A1492 32 16 18 10 not applicable
Percentage of simulation time when the base pairs were formed (i.e., at least one hydrogen bond
was present). Two values are shown for each simulation corresponding to two A-sites in the model.
(a) data from our previous study;85
(b) this base is U in G1491A, G1491U, WT and U1495C; and C in U1406C/U1495A simulation;
(c) this base is U in G1491A, G1491U and WT; C in U1495C; and A in U1406C/U1495A simulation;
(d) this base is A in G1491A, U in G1491U, and C in the other simulations.
Figure 4.16: Shift of base pairing pattern observed in some RNA simulations.
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Figure 4.17: Pseudo-dihedral angles describing
the variation in the conformations of nucleic
bases A1492 and A1493. The angle A1493 is cal-
culated as a torsion angle between the four atoms:
G1494(N1) – G1494(P) – A1493(P) – A1493(N1), as
depicted by black sticks (analogously for A1492:
G1494(N1) – G1494(P) – A1492(P) – A1492(N1)).
The exemplary values of the pseudo-dihedral an-
gles (in degrees) are shown in brackets. [Figure taken
from our published results211]
Mutations inuence the mobility of A1492 and A1493
In the wild type A-site, the most mobile bases are A1492 and A1493.11, 84, 85 These
adenines are in a dynamic equilibrium between the flipped out and flipped in conforma-
tions, and they form hydrogen bonds with the opposite A1408. We described the relative
conformations of A1492 and A1493 by defining pseudo-dihedral angles, relative to the suc-
ceeding base in the sequence, G1494 (Figure 4.17). This method of quantifying the mobility
of nucleic bases has been used before.83, 213–215 Thus measured different relative orientations
of the two adenines can be organized in three basic states:20–27
(A) both adenines occupy the inside of the RNA helix (A1492 2 [ 45; 50], A1493 2 [ 45; 40]);
this conformation prevents binding of an aminoglycoside and indicates a rejection of
a non- or near-cognate tRNA during a normal translation process (Figure 4.18A);
(B) A1492 is flipped out (A1492 <  45 or A1492 > 50) and A1493 occupies the inside
of the helix (A1493 2 [ 45; 40]); the recognition of the translation termination factor
requires this conformation (Figure 4.18B);
(C) both A1492 and A1493 are flipped out (A1492 <  45 or A1492 > 50, and A1493 <  45
or A1493 > 40), which indicates the acceptance of a cognate tRNA and also the easiest
access for an aminoglycoside (Figure 4.18C).
We checked whether the mutations affected the mobility of these bases. Figure 4.18
shows the sampling of the conformation space of A1492 versus A1493, observed in different
simulations. In the WT simulation, the adenines were dynamic and visited all the men-
tioned conformations. Compared to the WT simulation, the largest changes occurred in the
simulation with the doubly mutated U1406U1495 pair — in this case, the adenines were
almost never inside the RNA helix. On the contrary, the motion of A1492 and A1493 was
restricted to the flipped in conformations in the simulations G1491A and G1491U. Interest-
ingly, the least changes were introduced by the U1495C mutation. This can be also observed
through measuring the percentage of time when A1492 or A1493 occupied the flipped-in
state (Table 4.3). These adenines were inside the helix for a significantly shorter time in the
U1406C/U1495A simulation than in the WT. A similar trend was also observed for one part
of the model in the U1495C simulation, while for the two simulations with mutated G1491,
the occupancy of the flipped-in state was almost twice as large as in the WT simulation.
Both the G1491A and G1491U mutations were found to confer high levels of resistance
to paromomycin experimentally45, 47 (see Table 3.1). Our simulations showed that the occu-
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Figure 4.18: Mobility of A1492 and A1493 in the MD simulations quantified by the pseudo-dihedral
angles, A1492 and A1493 (see Figure 4.17 for the definition). The color shading in the plots reflects
the density of the points. Panels (A–C) show exemplary trajectory snapshots for each of the states
described in the text. [Figure taken from our published results211]
pancy of the flipped-in state of A1492 and A1493 increased upon these mutations, compared
to the WT simulation. The increased occupancy could lead to steric clashes with paromomy-
cin, which in general can have even larger effect than the alteration of electrostatic potential
in the binding site.14 We also found that in the G1491A simulation, the adenines were mov-
ing together most of the time (compare the area of (A) and (C) conformations with the area
of (B) conformations for the G1491A and WT simulations in Figure 4.18). The conformation
(B), i.e., with A1492 in the flipped-out and A1493 in the flipped-in state, is required when a
translation termination factor has to be recognized and accepted.22, 23 Therefore, the change
in the A1492 and A1493 movement introduced by the G1491A mutation could increase the
probability of a stop codon read-through. Although this correlation between the stop-codon
Table 4.3: Duration of the flipped-in conformations of A1492 and A1493.
G1491A G1491U U1495C U1406C/U1495A WT
A1492 65 46 74 55 0 42 3 1 26 20
A1493 87 79 78 51 19 58 0 21 61 79
Percentage of the simulation time when A1492 or A1493 was inside the helix. Two values are shown
for each simulation corresponding to two A-sites in the model.
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read-through and the G1491A mutation was previously reported,216 our simulations pro-
vide the first mechanistic insight and propose an explanation of this event.
Moreover, A1492 and A1493 occupied the inside of the RNA helix for a longer time
in the G1491A simulation than in G1491U. However, their mobility is required during the
normal translation process. Thus, this restraining may lead to worse “fitness” of bacteria
possessing a G1491A substitution, and explain why the mutation G1491U is more evolu-
tionary profitable, as was proposed earlier.51
4.2.3 Shapes and sizes of aminoglycoside binding pockets in RNA
Mutations of G1491 inuenced the shape of RNA binding site
The observed shifts of the base pairing pattern in the RNA A-site can potentially in-
fluence the volume and shape of the aminoglycoside binding site. The pocket boundaries
can be easily identified in proteins, where they often form deep cavities on a surface of
a globular-shaped molecule. Contrary, the binding cleft in the RNA does not have clear
boundaries. Nucleic acid helices have naturally long and wide cavities, called minor and
major grooves, and the area of the binding cleft depends on the aminoglycoside. Thus,
to describe the A-site binding pocket, we measured several distances between the atoms
pointing to the inside of the helix. Figure 4.19 shows the representative conformations of
the A-site pockets, together with the relevant intramolecular distances.
In comparison with the WT simulation, the mutations of G1491 changed the shape of
the cleft — it was more compact even though the bases A1492 and A1493 moved to the
flipped-in state in all three simulations (WT, G1491A, and G1491U). As can be seen, this
change in shape was caused by a shift of the base pairing and twisting of base 1491. In the
structures with mutations in the U1406U1495 pair, the conformations of the two adenines
were mostly flipped-out and led to a more open binding cleft.
Previous experimental studies hypothesized that the bonds formed between an amino-
glycoside and a G1491A mutated A-site were weaker than in the native complex due to the
less nucleophilic nature of an adenine than that of a guanine.42 However, our results point
to a different explanation, where an antibiotic could have difficulty fitting into the mutated
binding site because of the apparent change in the shape of the cleft.
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4.2.4 The U1406C/U1495A mutation changes the charge distribution
inside the A-site
Aminoglycosides require a specific electrostatic potential inside a binding site because
the majority of the interactions they form are of electrostatic nature.11, 217 We monitored the
distribution of sodium ions in our simulations of the bare A-site models to investigate the
change in the electrostatic potential of the paromomycin binding site, and to seek for any
changes in the distribution upon mutations.
Previously it was observed that in the WT A-site model, the sodium ions gathered close
to the phosphate groups of A1492 and A1493, and also in the position of the N3 group of par-
omomycin from the complex.85 The mutations of G1491 made the ions gather slightly closer
to the phosphate group of A1493 (by approximately 2 Å; Figure 4.20A–B). This indicated
only a small change in the electrostatic potential, most likely caused by the two adenines be-
ing in the flipped-in state for a longer period of time than in WT type A-site. In the U1495C
simulation, the area of maximal ion density was shifted  3 Å towards the major groove,
while the double mutation U1406C/U1495A caused the sodium ions to gather outside of the
binding site (Figure 4.20C–D). Since the ion density areas were not present close to the phos-
phate groups of A1492 and A1493, an aminoglycoside would have difficulties recognizing
the doubly mutated A-site as its binding site. This corroborates with previous studies,45, 85
which showed that the negatively charged groups of the U1406U1495 pair were important
for forming a complex with an aminoglycoside.
Figure 4.20: Areas of high sodium ion density in the free A-site models: (A)–(C) > 0:066 ions
per Å3, (D) > 0:055 ions per Å3; violet areas present the data from the WT simulation, and green
areas — from the simulations of the mutated structures. The superimposed position of paromomycin
is shown for clarity. Only the 1406, U1495, A1408, A1492, and A1493 bases are shown in atomic
details. Hydrogen atoms were not shown for clarity of the image. [Figure taken from our published results211]
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4.2.5 Short-range interactions formed by RNA with paromomycin
To investigate the atomic details of the A-site:PAR complex formation, we analyzed and
compared the interactions formed by the mutated A-site models with paromomycin. In the
crystal structure of the WT A-site complexed with paromomycin, ring I of the aminogly-
coside is positioned in the space created by the flipped-out A1492 and A1493, and forms a
pseudo-base pair with A1408.142 The majority of the hydrogen bonds in the crystal structure
are formed with rings I and II. In our WT_PAR simulation all of these hydrogen bonds were
maintained (Table 4.4).
atoms involved in H-bond occupancy of H-bond
[% of simulation time]
X-ray distance [Å]
PAR atom : : : RNA atom part A part B part A part B
O30: : :A1492(O2P) 95 96 2.90 3.13
O40: : :A1493(O2P) 96 94 2.54 2.84
O50: : :A1408(N6) 48 41 3.16 3.22
O60: : :A1408(N1) 94 95 2.53 2.57
N1: : :U1495(O4) 94 89 2.82 2.72
N3: : :A1493(O1P) 96 96 3.13 3.17
N3: : :G1494(N7) 84 78 2.78 2.51
N3: : :G1494(O2P) 90 34 3.12 3.17
O200: : :C1407(N4) 58 40 2.73 3.07
O500: : :G1491(N7) 44 65 2.71 2.74
N2000: : :G1405(O2P) 92 92 2.96 3.18
O3000: : :U1406(O2P) 95 90 4.42 4.35
Table 4.4: Direct hydrogen bonds formed between paromomycin and the ribosomal RNA A-site.
Only the interactions between paromomycin and a receptor’s residue that lasted at least 50% of the
simulation time in at least one of symmetric parts of the receptor are shown. The location of the bases
relative to paromomycin is illustrated in the left panel.
Mobility of paromomycin increases in the RNA with mutated U1406U1495 pair
Table 4.1 shows the RMSF values of paromomycin from each of the simulations of the
complexes. These values suggest that the drug’s mobility was increased in the complexes
with U1495C, U1406C/U1495A and G1491A mutation. The visualizations of the trajectories
showed that paromomycin’s position relative to the binding site changed substantially in
the U1406C/U1495A_PAR simulation (Figure 4.21). We quantified these observations by
measuring the distances between the centers of mass of paromomycin’s rings and the center
of mass of phosphorus atoms of A1492 and A1493. Figure 4.22 shows the histograms of
the measured values for rings I, III and the most distant ring IV. Paromomycin was farther
away from the adenines in the U1406C/U1495A_PAR simulation, in part A of the structure,
as indicated by the shift of  2 Å in the histograms for all rings. Moderate receding of paro-
momycin was also visible in part B of the U1495C_PAR structure. In contrast, paromomycin
in the G1491A_PAR simulation remained close to its initial position, even though its RMSF
value in part A was similarly high. The measurements revealed that the drug in part B
moved even closer to the adenines, as compared to WT_PAR. Similar, but less pronounced
effect, was observed in part A of the G1491U_PAR simulation.
As a result of the increased mobility of paromomycin complexed with the U1406C/U1495A
mutated A-site, the hydrogen bonds formed with ring II of the drug were broken. In the
crystal structure 1J7T,142 there are two important interactions between the drug and the
UU pair: (i) PAR(N1) forms a direct hydrogen bond with U1495(O4) (Table 4.4); and (ii) a
water-mediated hydrogen bond is formed between PAR(O6) and U1406(O4) (the distances
in the two parts of X-ray structure are 2.62 Å between PAR(O6) and the OW oxygen of
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water molecules W8 or W54; and 2.59 and 2.41 Å between W8(OW) and W54(OW), respec-
tively, and U1406(O4)). These two interactions were maintained throughout our WT_PAR
simulation. Moreover, in one part of the simulated structure, a direct hydrogen bond was
formed between PAR(O6) and U1406(O4) towards the end of the simulation (i.e., after ca. 11
and 14 ns in two parts of the structure, respectively). Similar behavior was observed in
the G1491A_PAR simulation (Figure 4.23A–B). In contrast, in the simulation of the doubly
mutated complex, paromomycin did not form any hydrogen bonds with 1495A and the in-
teraction with 1406C was formed sporadically (Figure 4.23C–E). As shown earlier, during
the U1406C/U1495A_PAR simulation, the drug changed its position relative to the binding
site, thus a different hydrogen bond was formed (Figure 4.23F), which led to destabilization
of the mutated base pair.
Our results demonstrated that the U1495C mutation exhibited smaller effect on paro-
momycin binding than the U1406C/U1495A substitution, which is in agreement with the
experimental studies that showed the MIC values for bacteria possessing different muta-
tions44, 45 (see Table 1.1). Hobbie et al. examined also the U1406C/U1495G mutation, which
disrupts the base pair geometry and maintains only the negative charge of base 1495. Sur-
prisingly, this substitution did not lead to significant rise in the MIC values, in contrast to
the other two mentioned mutations (see Table 1.1). Therefore, it seems like the negative
charge provided by the base in position 1495 is more important than the charge of the base
in position 1406 or even than the geometry of this base pair.
Figure 4.21: Change in paromomycin’s conformation in the A-site upon some mutations. The
structure with the double mutation U1406C/U1495A did not form a stably bound complex (compare
(A) with (B)), but also in one part of G1491A mutated A-site the drug changed its conformation (C).
[Figure taken from our published results211]
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Figure 4.22: Distance [Å] between the center of mass of A1492(P) and A1493(P) and the centers of
mass of paromomycin’s rings — histograms of values measured in the simulations.
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Figure 4.23: Hydrogen bonds formed between ring II of paromomycin and RNA. Distances be-
tween the atoms of the U1406U1495 pair and paromomycin as a function of the simulation time
along with the trajectory snapshots labeling the measured distances. Data taken from simulations
(A)–(B) G1491A_PAR and (C)–(F) U1406C/U1495A_PAR. Two plots depict values for the two A-sites
of the model. [Figure taken from our published results211]
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Figure 4.24: Representative structures of clusters from the MD simulations of A-site:PAR com-
plexes, superimposed with regard to the phosphorous atoms. Structures from each cluster are col-
ored differently: 1 — green, 2 — blue, 3 — red, 4 — yellow, 5 — cyan. Only paromomycin and bases
A1492, A1493, and A1408 are shown in atomic detail. [Figure taken from our published results211]
Range of movement of A1492 and A1493 is increased in the complexes of mutated RNA
A-site
These differences in stability of the complexes can be further strengthened by visual-
ization of the clustering of conformations from the MD simulations (Figure 4.24). All sim-
ulations of the mutated structures allowed for a wider range of movement of A1492 and
A1493 than WT_PAR. Especially in U1495C_PAR and U1406C/U1495A_PAR, the adenines
were much closer to the flipped in state. It has been suggested that the effectiveness of
aminoglycosides is correlated with the restriction of A1492 and A1493 to their flipped-out
positions,20, 218 and therefore, the visible widening of the range of their movement in the
simulations of mutated complexes versus the WT is in agreement with this hypothesis.
Experiments performed on the eukaryotic A-site with the A1491G substitution15 demon-
strated a minor decrease in the translation error frequency, while the presence of an amino-
glycoside caused a 10-fold increase of the error rate. This suggests that a reverse mutation
in bacteria would be very beneficial in terms of resistance and would carry a low cost of a
slight increase in the translation error rate in the absence of the drug. Our results provide
evidence for this theory. In the G1491A_PAR simulation, A1492 and A1493 moved closer
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to the flipped-in state than in the wild type complex simulation (Figure 4.24), which is an
indication of lower effectiveness of the drug.20, 218 Moreover, the flipped-in state was more
occupied in the simulation without paromomycin (G1491A). This can potentially lead to a
rejection of too many tRNA molecules and thus an increase in translation errors.
4.2.6 Water molecules inside the aminoglycoside binding site in RNA
The more resistance-causing mutation, the less water-mediated interactions are reproduced
In the complexes of aminoglycosides with the RNA A-site, non-direct (water-mediated)
interactions are often critical.31, 142 There are seven such interactions reported in the wild
type complex with paromomycin,142 all formed with the neamine core (i.e., rings I and II).
We calculated the average water density for the simulations of the A-site with different
mutations, with and without paromomycin.
(A) G1491A (B) U1406C/U1495A
Figure 4.25: Areas of high water density (light blue, > 0:23 water molecule per Å3) located in one
part of the simulated structures, superposed on the first frame of the complexes with PAR; only the
1406, 1495, A1408, A1492, and A1493 bases are shown in atomic details; spheres show the positions
of the crystal water oxygen atoms, those that were identified in the simulation are marked in orange
(see Table 4.5). Hydrogen atoms were not shown for clarity of the image.
[Figure taken from our published results211]
The water dense areas in the G1491U, G1491A, and U1495C simulations were less nu-
merous than in the U1406C/U1495A simulation (Figure 4.25). This might have been caused
by the change in the shape of the binding site due to the shift of base pairing (as observed
in G1491U and G1491A) or simply because A1492 and A1493 were positioned inside the
cleft (in all singly mutated structures). In contrast, much more water dense areas were iden-
tified in the simulation of the structure with the double mutation (Figure 4.25B). Many of
them were localized in the positions of paromomycin’s atoms from the superimposed crys-
tal structure. This suggests that the cleft was more “open” throughout the simulation and
that the drug would have to expel many water molecules when binding to this doubly mu-
tated A-site.
In the A-site:PAR crystal structure, 1J7T, there are many water molecules close to paro-
momycin. We checked whether our simulations of the complexes reproduced these molecules
(Table 4.5). In the WT_PAR simulation, 12 areas of high water density were located in
positions of the superimposed crystal water molecules, including all 7 that helped create
the water-mediated polar contacts. Similar case was with the G1491U_PAR simulation, for
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which only W19 was not reproduced. The other mutation of G1491 led to more changes in
the interactions with paromomycin and only eight water dense areas were close to the po-
sitions of the crystal water molecules, of which only three represented the water-mediated
hydrogen bonds. This shows that the G1491A mutation influenced the complex stability.
Although in the U1406C/U1495A simulation, there were many water dense areas, in the
simulation of the complex, only two water-mediated contacts were reproduced and only six
crystal water molecules in total. This again demonstrates that the double mutation resulted
in the weakest bound paromomycin.
Table 4.5: Reproduction of the crystal water molecules in simulations of the A-site:PAR complexes.
water molecule # G1491U_PAR G1491A_PAR U1406C/U1495A_PAR U1495C_PAR WT_PAR
W1 +   + + +
W4 + + + + +
(W7) ( ) ( ) ( ) ( ) ( )
W8 (W54) (*) +( )  (+) +( )  ( ) +( )
W9 (W2) (*) +(+)  (+)  (+) +(+) +(+)
W12          
W13 (*) +       +
W14 (*) + + + + +
W15          
W19 (*)         +
W20   +   + +
W25 + + + + +
W27 +        
W28 +     +  
W32 (*) + +   + +
W44 (*) + +   + +
(W45) ( ) ( ) ( ) ( ) ( )
W49 + + +(near) + +
W51   + + +  
Selected water molecules of the 1J7T crystal structure and the corresponding high water density
areas in the MD simulations with paromomycin. “+” denotes water density areas higher than 0.22
water molecules per Å3 observed in the position of the corresponding crystallographic water
molecule; “ ” denotes lack of high water density in this position. Brackets denote water molecules
located in the second symmetric part of the RNA fragment. [Table taken from our published results211]
(*) these water molecules mediate the non-direct hydrogen bonds between paromomycin and RNA
in the original crystal structure, 1J7T142
4.2.7 Proposed modications of paromomycin
Based on our observations from the MD simulations, some modifications to paromomy-
cin can be proposed. Please refer to Figure 3.3A for numbering of paromomycin atoms, and
to Table 4.4 for the hydrogen bonds formed in the WT A-site:PAR complex. Concerning the
mutations of the U1406U1495 bases, a substitution of the 2000–NH+3 group with 2
000–CH2NH+3
could improve the A-site:PAR stability, because it would allow the ring IV to interact with
the phosphate groups of both G1405 and U1490 or G1491, and thus, paromomycin would
anchor more in the mutated A-site. This modification would also increase the stability of the
complexes with mutated G1491, since we observed that paromomycin ring IV in these com-
plexes formed hydrogen bonds with the RNA backbone, i.e., interactions between 2000–NH+3
of paromomycin and G1405(O2P), and/or 6000–NH+3 and O2P of the mutated base 1491.
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To strengthen the direct interactions with ring II, the 6–OH group of paromomycin
could be substituted for CH2OH. This would enable creation of a direct hydrogen bond
between U1406(O4) and PAR(O6), instead of a water-mediated one observed in the WT
structure84, 142 and in our WT_PAR simulation. Perhaps even farther strengthening could be
achieved when swapping the amino group at 20 position (ring I) with the OH substituent
at 30 position. The hydrogen bond between 30–OH and A1492(O2P) was less stable in the
G1491A_PAR and the U1406C/U1495A_PAR simulations than in the WT_PAR, and a 30–
NH+3 group would form a stronger interaction with the phosphate.
As has been shown, the least stably bound paromomycin was in the U1406C/U1495A_PAR
simulation. One of the important interactions in the WT complex involve the 3–NH+3 of par-
omomycin (ring II) and the phosphate groups of either G1494 or A1493, which was not
maintained in the simulation of the doubly mutated complex (after the equilibration, there
was an increase in distance from  3:9 Å up to 4:9 Å). Therefore, an extension at this posi-
tion (i.e., 3–CH2NH+3 instead of an amine group) could improve binding, which may also
diminish the effect of the double mutation U1406C/U1495A.
4.2.8 Summary
The results from our MD simulations of the A-site model with different mutations
showed that the mutations influence different features of the paromomycin binding site.
We have demonstrated that a substitution at position 1491 changed the base pairing pattern,
which led to a more compact binding site. The shape of this binding site appears to be an
important factor of aminoglycoside affinity towards the A-site, and therefore the change in-
troduced by the G1491 mutations hinders binding. The mobility of A1492 and A1493 was
also affected in our G1491A and G1491U simulations, resulting in the adenines occupying
the flipped-in state for most of the simulation time. Moreover, the G1491A mutation made
the adenines move together more often than in WT. This observation helps explain the in-
creased stop codon read-through of the bacterial ribosomes carrying this mutation — the
recognition of a termination factor requires that only A1492 be flipped-out, while A1493
stays inside the helix. Since this conformational state of the adenines was sampled less often
in the G1491A structure, it is more likely that a termination factor would be rejected by the
mutated ribosome.
The outcomes of the simulations of structures with the mutated U1406U1495 pair con-
firmed that these bases are important for aminoglycoside binding. They provide the nega-
tively charged moieties that form hydrogen bonds with all aminoglycosides binding in this
site. Therefore, when the uridines are mutated, an aminoglycoside may have difficulties
in recognizing this cleft as its binding site. The double mutation introduced the most pro-
nounced changes in our simulations, which is in agreement with the MIC studies that found
that bacteria possessing this mutation were highly resistant to almost all aminoglycosides.
Our U1406C/U1495A_PAR simulation showed that the complex with paromomycin was
not stable and the range of movement of A1492 and A1493 was much wider than in the
WT_PAR simulation. Aminoglycoside efficiency has been shown to correlate with the de-
gree of adenine mobility restraint. Therefore, our simulations of the complexes qualitatively
confirm this result.
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4.3 Bacterial resistance mechanism 2: enzymatic aminoglycoside
modication
To gain a more complete view on bacterial resistance mechanisms against aminogly-
cosides, we studied the most common mechanism, i.e., when bacteria produce enzymes
(AMEs) that chemically modify aminoglycosides and inactivate them. We selected three
enzymes: AAC(60)-Ib, ANT(40) and APH(30,500)-IIIa. The ANT representative is active as a
homo dimer, and contains two aminoglycoside binding sites, both occupied by kanamycin A
in our ANT_HOLO simulations. Conversely, AAC and APH are active in their monomeric
states. Below, we present the results from these MD simulations of AME representatives
and their complexes with kanamycin A and from a simulation of the A-site:KAN complex,
which was conducted as a reference. For the detailed list of the selected structures and
performed simulations, see Tables 3.2 and 3.3 in Chapter 3.
4.3.1 Conformations of bound kanamycin A
To study the conformational diversity of kanamycin in our simulations, we employed
the same measure as in the case of paromomycin, i.e., we monitored the ffi= dihedral angles
of the linkages (see Section 3.3.2 Parameterization validation for the definition). Figure 4.26
gathers the results from these measurements. Kanamycin’s conformation in the complex
with the rRNA A-site was similar to the one that we found to be the most occupied in water
(compare Figure 4.26, top, with Figure 3.4C–D). Linkage I/II acquired the same ffi/ val-
ues for both aminoglycosides complexed with the native A-site (KAN and PAR; compare
Figure 4.26, top with Figure 4.12, top). Notably, the kanamycin’s conformation in two of
the studied enzymes (AAC and APH) was very similar to the one in the A-site. However,
binding to ANT required a drastic conformational change in linkage I/II and also made link-
age II/III more dynamic. This suggests that ANT binds kanamcyin A less tightly than other
enzymes. Previously reported X-ray and NMR experiments67, 68, 79 showed that the con-
formation of several aminoglycosides bound to some AMEs is significantly different from
the one adopted in the A-site. This fact was utilized to propose some conformationally
constrained aminoglycoside derivatives80, 219 that disabled their binding to AMEs. How-
ever, that strategy is very limited, since even if an aminoglycoside changed its conformation
when binding to one AME, in the complexes with other AMEs the conformation would be
the same as acquired inside the A-site, and therefore constraining aminoglycosides would
not prevent binding to all possible bacterial AMEs.
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Figure 4.26: Conformations of kanamycin A bound to different receptors. On the left, the most pop-
ulated conformations from the simulations are presented. The graphs depict changes of the dihedral
angles of the linkages between the rings.
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4.3.2 Internal dynamics of enzymes
Flexibility patterns dier among AMEs
The rRNA A-site bulge is flexible, and we have shown that even one-base substitutions
can change its internal dynamics. To investigate the dynamic features of AMEs, we looked
at the differences in RMSF between the APO (i.e., binary complex: enzyme + cofactor) and
HOLO (i.e., ternary complex: enzyme + cofactor + kanamycin A) states of the enzymes.
This difference in the residue fluctuations of each enzyme is presented in Figure 4.27. The
monomeric enzymes, i.e., AAC and APH, displayed the biggest changes in the residue mo-
bility upon kanamycin A binding, especially the loops located over the binding site were
restrained in the HOLO states. On the contrary, the changes in RMSF between the APO and
HOLO simulations were much smaller for the dimeric ANT. Moreover, this enzyme was the
least dynamic from all three structures, as indicated by the range of RMSF values presented
in Figure 4.28.
Figure 4.27: Difference in internal dynamics between the HOLO and APO states of the enzymes,
presented as the difference in per-residue RMSF [Å] calculated for all simulations; the negative values
point to more mobile residues in the APO state. The residues that had abs(RMSF) > 0:5; 0:3 or 0:4 Å
for APH, AAC and ANT, respectively, are labeled.
Figure 4.28: Histograms of the per-residue RMSF values from the simulations of AMEs; compari-
son between the residue mobility in the APO and HOLO states.
We studied the enzymes’ dynamics with our new tool, GeoStaS, that analyzes the differ-
ences and similarities in molecular motions. The GeoStaS analysis of the trajectories shows
the division of AMEs into dynamic domains (presented in Figure 4.29). The results indicate
that the flexibility patterns did not change upon kanamcyin binding for both ANT and AAC.
In contrast, the APH enzyme displayed significantly different pattern of fluctuations in the
APO and HOLO simulations. To analyze this finding further, we collected all other exper-
imental structures of AAC and APH, that were available in PDB. Then we performed PCA
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on those structures and projected the conformations from the simulations onto the identified
principal components. In the case of APH X-ray structures, both PC 1 and PC 2 describe
the movement of the aminoglycoside binding loop (i.e., residues from around Asp 150 to
Asp 162) and of the cofactor binding loop (i.e., residues from around Asp 22 to Ser 27),
as illustrated in Figure 4.30A. In the case of AAC, PC1 shows large movements within the
residues positioned close to the cofactor binding site and the loop over the aminoglycoside
binding site (i.e., residues from Glu 47 to Arg 55). Indeed, three residues from this loop are
not present in several X-ray structures. PC2 of the AAC conformations describes a rather
moderate movement of the loop over the aminoglycoside binding cleft. The first mode is
depicted in Figure 4.30B. The conformations from X-ray studies and simulations projected
onto PC1 versus PC2 plane yield the so-called conformer plots, presented in Figure 4.31.
The results demonstrate that the range of conformational sampling of APH and AAC was
diminished upon binding of kanamycin A. This restriction in dynamics was much more
pronounced in the case of APH. Moreover, the sampled conformations were close to those
that were resolved in the complexes with some other ligands, which demonstrates the high
flexibility of APH and AAC.
Only one experimental structure has been resolved of the dimeric ANT. Consequently,
the conformer plot analysis were not suiting. Thus, we performed clustering of all simulated
conformers sampled along the six independent simulations to investigate whether some
Figure 4.29: Dynamic domains found by GeoStaS based on conformations from the AME tra-
jectories: (A) AAC_APO, (B) AAC_HOLO, (C) ANT_APO, (D) ANT_HOLO, (E) APH_APO, and
(F) APH_HOLO. Each structure is colored independently. The enzymes are presented in cartoon,
and the ligands — in sticks.
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conformations appear both in the APO and HOLO simulations. Figure 4.32 shows that ANT
sampled different states in the simulations with and without kanamcyin A, i.e., clusters were
not shared between the APO and HOLO simulations.
Our results demonstrate that each of the simulated enzymes displayed different flexibil-
ity pattern, which perhaps determines the way of gaining specificity for aminoglycosides.
The studied dimer, ANT, was the least flexible, which could explain the unique order of
binding of the substrates: ATP binds after an aminoglycoside. The binding of a drug to the
binary complex ANT:ATP would probably be more difficult since there could be not enough
space for the drug to adapt to the non-flexible binding site. Another hypothesis has been re-
cently formulated, as a result of experiments and short simulations of the binary and ternary
complexes of ANT(40).220 This new hypothesis suggests that binding of an aminoglycoside
is two-fold: first, when there is no ATP, an aminoglycoside binds non-specifically, and the
relocation to the main binding site is triggered by the presence of the nucleotide.
In our simulations, the monomeric AAC was more dynamic than ANT. Specifically
the loops positioned over the aminoglycoside binding site were flexible. However, our re-
sults show that this pattern of internal dynamics did not change when kanamycin A bound
to AAC. Thus in this case, the global conformation of the enzyme could be similar when
forming complexes with different drugs. Moreover, since the structure of the studied AAC
resembles the structures of other enzymes from the AAC(60) subfamily, this mobility pattern
may be similar for the subfamily. However, this should be investigated further.
The APH enzyme was the most flexible in the APO simulations, and it adopted many
conformations that resembled the experimental conformations of its complexes with differ-
ent aminoglycosides. While the NMR experiments suggested a highly disordered struc-
ture of APH,75 the X-ray studies were able to capture well the unliganded enzyme and
enzyme:cofactor complexes. Our results may explain this contradiction — APH is in a dy-
namic equilibrium between different thermally accessible conformations thus one may be
able to observe a well defined conformation in a crystal. Our analysis demonstrated that
when complexating with a drug, APH becomes more rigid, which indicates that this pro-
cess carries a high entropic cost. We hypothesize that it is probably in order to lower this
entropic cost that APH(30,500) sometimes forms dimers.73
Figure 4.30: Visualization of the first PC for the APH and AAC X-ray structures, presented as the
backbone trace of two most extreme conformations, colored black and red, respectively. The most
dynamic loops in APH are encircled and labeled; kanamycin A (green sticks, in both structures) and
ACO (blue sticks, in AAC) are superimposed for reference.
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Figure 4.31: Comparison of the trajectory-derived conformations (shaded gray dots) with the ex-
perimental structures of the AAC and APH enzymes (colored points). The plots show differences
in conformations based on the two first PCs, which constitute 74.2% and 98.7% of the conforma-
tion variance for APH and AAC X-ray structures, respectively. The structure of the unliganded wild
type enzyme is marked by a red square, the enzymes complexed with a coenzyme only are colored
blue, the ternary complexes (enzyme + coenzyme + antibiotic or inhibitor) are in orange, and the
unliganded mutated enzyme in cyan.
Figure 4.32: Clustering of
ANT conformations sam-
pled in all the simulations
— each color bar in the bot-
tom of the graph represents
a different cluster. Black line
shows the RMSD for each
of the trajectories, with re-
spect to each starting confor-
mation.
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Figure 4.33: Histograms of aminoglycoside binding site volume [Å3] in the simulations of the
A-site and AMEs.
4.3.3 Shapes and sizes of aminoglycoside binding pockets in AMEs
Volume of binding pocket is greatly reduced upon aminoglycoside binding in APH
We measured the volume of kanamycin A binding sites to compare the pockets among
the selected AMEs and between AMEs and the rRNA A-site. Therefore, when defining the
space of the pocket on the RNA, we have decided to include only the space that would be
occupied by kanamycin A. However, we note that an aminoglycoside of different shape and
size could also fit into the pocket and could give different volume values because this RNA
structure is flexible and the cavity is long and wide. Figure 4.33 compares the volumes of
the binding pockets in AMEs from the APO and HOLO simulations of each enzyme, and the
volume of kanamcyin A binding site from the simulations of the A-site. In the RNA:KAN
complex, the histogram was narrowed to the larger values compared to the simulation of
the bare RNA, because the adenines A1492 and A1493 were restricted to their flipped-out
conformation. Both for AAC and ANT the cleft’s volume did not change upon binding
of kanamcyin. In contrast, the space available for an aminoglycoside in APH_HOLO was
much smaller than in APH_APO. Together with the previously described results on the
internal dynamics of this enzyme, this suggests that the residues around the aminoglycoside
binding site in APH are very flexible and the enzyme adapts to the shape of aminoglycosides
when forming the complex, which suggests an induced fit mechanism of binding.
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Figure 4.34: Comparison of the elec-
trostatic potential in the aminoglyco-
side binding clefts of different AME
X-ray structures (indicated by PDB ID,
described in Table 3.2). The scale rep-
resents the root mean square distance
between the calculated potentials, rel-
ative to rings I and II of kanamycin A
(i.e., the neamine core).
4.3.4 Electrostatic potential inside aminoglycoside binding sites
The binding of aminoglycosides to the A-site has previously been shown to be domi-
nated by electrostatic interactions,217 due to the high charges on both, aminoglycosides and
RNA. Therefore, we analyzed the electrostatic potential (ESP) inside the binding sites of the
selected biomolecules. In the case of AMEs, the ESP was calculated directly for each of the
static X-ray structures (see Table 3.2 in Chapter 3), through the Poisson-Boltzmann contin-
uum electrostatics methodology (as described in Chapter 2, Section 2.7.1 Poisson-Boltzmann
model). We then used the Surface Diver179 software to compare the calculated ESP from
the point of view of the neamine core positioned inside the aminoglycoside binding site in
AMEs (see Section 3.4 Data analysis for the description of this method). Neamine is the com-
mon part of the majority of aminoglycosides, therefore each enzyme should create a very
similar electrostratic environment for this moiety.
Figure 4.34 shows the root-mean-square (RMS) distance between the ESP values for
the pairs of enzymes, separately for the part that originates from the positive and negative
charges. The maximal difference for the negative part of ESP was much larger (RMS distance
6 2:06) than for the positive part (RMS distance 6 0:805). This is because the binding
sites need to be negatively charged to attract the positively charged aminoglycosides, and
therefore the positive part of the ESP was negligible. In general, the enzymatic binding
sites differed in the negative part of ESP, with the 1L8T structure being the most distinct
from the others. It even differed from 1J7L, which is a dimeric version of the same enzyme.
This might be caused by the loop positioned over the binding site, which is “closed” in the
monomeric and “open” in the dimeric X-ray structure.
Table 4.6: Common chemical features of the amino acids inside the aminoglycoside binding sites
in AMEs.
number of chemical groups
chemical group type # 1KNY 1M4I 1S3Z 1V0C 1L8T
acceptor 15 14 12 10 16
donor 2 6 13 9 11
aliphatic 1 4 5 0 3
aromatic 0 3 4 6 3
The number of chemical groups of each type is shown based on the classification of amino acids
presented in Ref.221 The enzymes are labeled by their PDB code — for description see Table 3.2.
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4.3.5 Short-range interactions formed by the receptors with kanamycin A
Comparison of AME:AG X-ray complexes
Next, we investigated how the different AMEs interact with aminoglycosides. We com-
pared the amino acids that interact with aminoglycosides in different X-ray structures of the
AME:AG complexes. While the amino acids that are within 5 Å from the bound antibiotic
differed in type, the chemical groups they display were similar. As presented in Table 4.6,
the most common groups were acceptors of hydrogen bonds. This is due to aminoglyco-
sides having many NH+3 groups, which can act as donors. In the three structures, 1S3Z,
1V0C, and 1L8T, apart from hydrogen bond acceptors there was also a similar number of
donors. This can possibly help these enzymes be more promiscuous. The other types of
chemical groups were poorly represented inside the AME binding sites. Notably, even aro-
matic groups were rare, although they could form stacking interactions with the rings of
aminoglycosides. Only in the binding site of 1V0C (AAC(60)-Ib) a substantial number of
aromatic groups could be found.
Kanamycin A in the rRNA binding site
The performed simulations (see Table 3.3) focused on interactions of AMEs with one
aminoglycoside, kanamycin A. However, first, we studied the A-site:KAN complex, to be
able to compare and relate it to the AME complexes. Although kanamycin A has a slightly
different chemical structure and shape than paromomycin, it binds to the rRNA A-site in a
similar manner, utilizing mainly its two first rings (eight out of eleven hydrogen bonds are
formed with rings I and II).31 In our WT_KAN simulation, all the hydrogen bonds from the
crystal structure were maintained, even though some lasted shorter in one of the binding
sites of the model than in the other, as can be seen from Table 4.7.
atoms involved in H-bond occupancy of H-bond
[% of simulation time]
X-ray distance [Å]
KAN atom : : : RNA atom part A part B part A part B
O200: : :G1405(O6) 66 95 2.78 3.09
N300: : :G1405(N7) 72 74 3.06 2.91
N60: : :A1408(N1) 72 36 2.89 3.53
O30: : :A1492(O2P) 91 93 2.63 2.94
O40: : :A1492(O2P) 1 55 3.89 4.65
N3: : :A1493(O1P) 21 92 3.07 3.04
N60: : :A1493(O2P) 0 53 4.72 3.65
O40: : :A1493(O2P) 91 33 2.65 2.7
N3: : :A1493(O2P) 68 2 4.46 3.65
N3: : :G1494(O2P) 91 90 2.89 2.77
N3: : :G1494(N7) 73 48 2.81 2.66
N1: : :U1495(O4) 83 97 2.57 2.63
Table 4.7: Direct hydrogen bonds formed between kanamycin A and the ribosomal RNA A-site.
Only the interactions between kanamycin and the receptor’s residue that lasted at least 50% of the
simulation time in at least one of symmetric parts of the receptor are shown. The location of the bases
relative to kanamycin A is illustrated in the left panel.
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AMEs mimic hydrogen bonding with KAN from the A-site:KAN complex
Next, we analyzed the simulations of the complexes that AMEs formed with kanamy-
cin A. Compared to the complex formed with the A-site, slightly less hydrogen bonds were
formed in the AAC_HOLO simulations (nine or eight, depending on the simulation run),
while in the ANT_HOLO simulations, they varied from 6 to 12. The APH:KAN complex
was the most stable, with 14 hydrogen bonds in each of the APH_HOLO simulation runs.
The complete lists of hydrogen bonds formed in the binding sites are presented in Tables 4.8–
4.10.
Naturally, since the aminoglycosides are positively charged in physiological pH, they
are attracted by the negatively charged RNA backbone. We found that AMEs mimic these
interactions quite well (Figure 4.35A–B). During the simulations, the enzymes formed many
hydrogen bonds utilizing the Asp and Glu side chains. However, there were several cases
where other amino acids formed equally stable interactions (Figure 4.35A), e.g., Ser 94 in
the ANT_HOLO simulation (in both monomers), Ser 98 in AAC_HOLO and Phe 264 in
APH_HOLO. The first two mentioned interactions were created through carbonyl groups
of the backbone. Phe 264 is the terminal residue in APH(30,500), and therefore, it utilized
its backbone carboxyl group, forming hydrogen bonds through either of the oxygens. This
interaction was shown to be conserved within the APH(30) subfamily.222
Table 4.8: Direct hydrogen bonds formed between kanamycin A and AAC(60)-Ib. Only the interac-
tions between kanamycin and a receptor’s residue that lasted at least 50% of the simulation time in
at least one of the simulations are shown. See Figure 4.35 for the kanamycin A atom numbering and
the location of the amino acids.
atoms involved in H-bond occupancy of H-bond
[% of simulation time]
KAN atom : : : enzyme atom sim 1 sim 2 sim 3
O200: : :Glu73(OE1) 0 25 0
O200: : :Glu73(OE2) 0 33 0
O400: : :Glu73(OE1) 15 3 39
O400: : :Glu73(OE2) 29 0 26
N300: : :Glu73(OE1) 29 60 26
N300: : :Glu73(OE2) 24 48 13
O5: : :Gln91(NE2) 91 96 95
N1: : :Ser98(O) 0 57 17
N60: : :Asp115(OD2) 96 92 95
N3: : :Asp115(OD2) 95 86 88
N3: : :Asp152(OD1) 55 19 58
N3: : :Asp152(OD2) 75 19 62
O40: : :Asp179(OD1) 31 23 3
O40: : :Asp179(OD2) 20 21 3
N60: : :ACO(O) 87 85 83
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Table 4.9: Direct hydrogen bonds formed between kanamycin A and APH(30,500)-IIIa. Only the in-
teractions between kanamycin and a receptor’s residue that lasted at least 50% of the simulation time
in at least one of the simulations are shown. See Figure 4.35 for the kanamycin A atom numbering
and the location of the amino acids.
atoms involved in H-bond occupancy of H-bond
[% of simulation time]
KAN atom : : : enzyme atom sim 1 sim 2 sim 3
N60: : :Glu157(OE1) 66 31 42
N60: : :Glu157(OE2) 70 70 29
N3: : :Glu157(OE1) 15 0 66
N3: : :Glu157(OE2) 86 0 33
O5: : :Glu157(OE1) 0 57 0
O5: : :Glu157(OE2) 0 33 0
N1: : :Asn158(O) 92 36 94
N1: : :Glu160(OE2) 100 96 100
N300: : :Glu160(OE1) 90 95 97
O200: : :Glu160(OE2) 100 100 100
O30: : :Asp190(OD1) 0 40 95
O30: : :Asp190(OD2) 0 40 3
N300: : :Arg226(O) 41 0 82
N300: : :Glu230(OE1) 51 57 61
N300: : :Glu230(OE2) 44 65 42
O400: : :Glu230(OE1) 26 52 0
O400: : :Glu230(OE2) 18 44 0
N3: : :Asp261(O) 28 85 72
N1: : :Glu262(OE2) 100 92 100
N3: : :Glu262(O) 64 0 15
N60: : :Phe264(O) 0 67 63
N60: : :Phe264(OXT) 0 78 82
N3: : :Phe264(O) 67 76 68
O40: : :Phe264(O) 50 0 1
O40: : :Phe264(OXT) 52 0 0
O30: : :ATP(O3G) 99 0 3
O40: : :ATP(O3G) 0 0 90
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Table 4.10: Direct hydrogen bonds formed between kanamycin A and ANT(40)-I. Only the interac-
tions between kanamycin and a receptor’s residue that lasted at least 50% of the simulation time in
at least one of the simulations are shown. The values in brackets refer to the hydrogen bonds formed
in the second monomer. See Figure 4.35 for the kanamycin A atom numbering and the location of
the amino acids.
atoms involved in H-bond occupancy of H-bond
[% of simulation time]
KAN atom : : : enzyme atom sim 1 sim 2 sim 3
O40: : :Glu52(OE2) 0 (0) 86 (0) 0 (0)
N60: : :Glu52(OE2) 0 (0) 0 (0) 99 (0)
O20: : :Glu67(OE1) 50 (88) 100 (62) 7 (28)
O20: : :Glu67(OE2) 50 (3) 0 (31) 1 (73)
N3: : :Glu67(OE1) 66 (46) 99 (56) 27 (59)
N3: : :Glu67(OE2) 66 (72) 14 (48) 86 (59)
O20: : :Lys74(NZ) 0 (43) 0 (6) 0 (70)
N60: : :Glu76(OE1) 61 (12) 6 (1) 92 (56)
N60: : :Glu76(OE2) 56 (96) 11 (99) 54 (73)
O30: : :Glu76(OE2) 0 (0) 76 (0) 0 (0)
N3: : :Glu76(OE2) 0 (56) 0 (72) 0 (0)
N1: : :Glu93(OE1) 13 (0) 0 (0) 88 (0)
N1: : :Glu93(OE2) 29 (0) 0 (0) 6 (0)
N300: : :Ser94(O) 0 (0) 0 (0) 89 (1)
N300: : :Asp95(OD1) 8 (0) 0 (39) 64 (4)
N300: : :Asp95(OD2) 2 (3) 0 (24) 38 (0)
O20: : :Glu141(O) 0 (0) 0 (0) 88 (0)
O30: : :Glu141(O) 66 (0) 0 (0) 0 (0)
N3: : :Glu141(OE1) 27 (0) 0 (0) 0 (60)
N3: : :Glu141(OE2) 35 (43) 99 (2) 99 (37)
O200: : :Glu142(OE1) 58 (71) 72 (12) 98 (92)
O200: : :Glu142(OE2) 31 (22) 41 (36) 1 (13)
N1: : :Glu142(OE1) 0 (11) 0 (21) 0 (3)
N1: : :Glu142(OE2) 9 (33) 1 (12) 94 (80)
N300: : :Glu142(OE1) 0 (0) 0 (42) 0 (0)
N300: : :Glu142(OE2) 0 (0) 0 (24) 0 (0)
O30: : :Glu145(OE1) 1 (30) 1 (52) 0 (15)
O30: : :Glu145(OE2) 1 (52) 21 (76) 93 (9)
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Figure 4.35: Similar interactions formed with kanamycin A in different binding sites.
(A) The hydrogen bonds lasting at least 50% of the simulation time formed with kanamycin A in
different binding sites: rRNA A-site — black; AAC(60)-Ib — red; APH(30,500)-IIIa — green; ANT(40)
— blue. Although the amino acids involved in forming the hydrogen bonds differ, the types of
interactions were similar: the solid lines encircle the interactions with the phosphate or carboxyl
groups, and the dashed lines — with carbonyl group. Few exceptions are denoted in parentheses
next to the residue name. The colored circles around kanamycin A atoms mark the modification sites
for each of the AMEs.
(B) The oxygen atoms that formed the hydrogen bonds (small spheres) during the simulations are
positioned similarly in space, as illustrated by the average structures of receptors superimposed with
respect to ring II of kanamycin A (dark gray lines): RNA (pink), AAC (green), ANT (magenta) and
APH (cyan).
(C) The non-polar interactions in various receptors were formed with residues that have similar
location, relative to kanamycin A (coloring and representation is the same as in panel B).
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Non-polar interactions with KAN are similar in dierent receptors
Another type of interaction formed between RNA and aminoglycosides is stacking.31, 142
While classic stacking occurs between two aromatic moieties, sugar–aromatic stacking is
also frequently observed.223 In the A-site complexed with an aminoglycoside, ring I fits in
the vacant space next to the flipped-out A1492 and A1493, and it stacks on top of G1491 (Fig-
ure 4.36A). Since this interaction is common to all aminoglycosides that bind to the A-site,
we have checked whether it is copied by the enzymes (see Section 2.6 Intra-molecular inter-
actions in Chapter 2 for the measurement details). In the WT_KAN simulation, the stacking
between ring I and G1491 below was maintained throughout the simulation in both parts
of the structure (mean distance: 4:15  0:21 Å, mean cosine: 0:977  0:021). In the AME
simulations, only in the AAC binding site the aromatic residues were close enough to kana-
mycin to form stacking. These were: Trp 49 (stacked with ring I of the drug), Tyr 93 and
Trp 102 (both stacked with ring II) (Figure 4.36B). These interactions were generally main-
tained throughout the simulation, with some short events of Trp 102 receding from ring II
of kanamycin (Figure 4.36C). In the other studied enzymes no stacking was observed, al-
though in APH_HOLO, van der Waals interactions were formed with the drug through two
arginines, Arg 211 and Arg 226 (colored cyan in Figure 4.35C).
Figure 4.36: Stacking interactions formed with kanamycin A in different receptors. (A) Kanamy-
cin A (magenta sticks) complexed with the A-site model; ring I of kanamycin is involved in stacking
interactions with G1491 (shown as sticks). (B) A snapshot from the AAC_HOLO simulation showing
the relative position of kanamycin A (magenta sticks) and the three amino acids involved in stacking
(grey sticks). (C) The stacking interactions between AAC and kanamycin A, measured as: a cosine
of the angle formed by two vectors perpendicular to the planes of the rings (plotted as points; a
value close to 1 or  1 indicates a parallel orientation); and the distance between the rings involved
in stacking (plotted as lines).
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4.3.6 Water molecules inside aminoglycoside binding sites in AMEs
In the complexes of aminoglycosides with the RNA A-site, non-direct (water-mediated)
interactions are often critical.31, 142 Although there were no such interactions reported in the
crystal structure of RNA:KAN complex,31 we monitored the water density in the binding
clefts in the AME:KAN complexes. Additionally, since the simulations were performed with
the all-atom representation of water molecules, we could investigate the mobility of these
individual particles.
Figure 4.37: Areas of high water density (> 0:06, > 0:07 and > 0:085 water molecule/Å3 for
AAC_HOLO, ANT_HOLO, and APH_HOLO, respectively) around kanamycin A (in green) in the
complexes with AMEs shown as blue surfaces and superimposed on average structures calculated
for one of the three independent simulations; the transparent surface represents the water accessi-
ble surface of the enzyme. The yellow circles mark the areas that were invariant in all ANT_HOLO
simulations.
Water molecules in AME binding sites provide additional stability of the complexes
The average water density areas in the AME binding sites are presented in Figure 4.37.
Different density values had to be set for each of the AME:KAN complexes — in AAC_HOLO
even for values as low as 0:06 water molecules per Å3 the areas were well defined, while in
APH_HOLO and ANT_HOLO the visualization required higher water density thresholds.
This demonstrates that in the AAC_HOLO simulation, the water molecules did not gather
around the bound drug, in contrast to other AME simulations.
Inside the ANT binding site, many water dense areas were located between the atoms of
the enzyme and the drug, which suggests that several indirect hydrogen bonds were formed
in this complex. Moreover, since the antibiotic was quite dynamic inside the ANT cleft, the
positions of these areas differed slightly in each binding site, with only a few conserved
areas, which are marked in Figure 4.37B. In contrast, the areas of high water density in
AAC_HOLO were farther away from kanamycin A, indicating a vacant space where another
aminoglycoside of different shape could fit (Figure 4.37A).
A few high water density areas in APH_HOLO were located between the drug and
Arg 211, Arg 226, Ile 258, Asp 261, and Glu 262, indicating that a complicated network of
hydrogen bonds was formed with these residues. Figure 4.38A presents an exemplary snap-
shot from the APH_HOLO simulation, which illustrates this network of hydrogen bonds.
The water molecules that were part of these interactions interchanged with the bulk water,
but the pattern of the hydrogen bonds was preserved throughout each of the three separate
APH_HOLO simulations.
Similarly, in AAC_HOLO, some dense areas were positioned near ring II of the antibi-
otic and residues Asp 152, Asp 179 (Figure 4.38B). Also here, these dense areas symbolize a
hydrogen bond network formed between these amino acids. As previously mentioned, in
the third complex, ANT:KAN only a few water dense areas were invariant between different
simulation runs and binding sites. These pointed to additional polar interactions formed by
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the enzyme with kanamycin A, through the water molecules: (i) between the backbone moi-
eties of Glu 141, Glu 142 and the oxygen O5 of KAN; (ii) between N1 of KAN and Glu 92,
Ser 94, Asp 95; and (iii) between N3 of KAN and Glu 67, Glu 76 (Figure 4.38C).
In each simulation of the AME:KAN complexes, one or more water molecules were
exceptionally stable, with the calculated -factor 6 30 Å2. While some of these “trapped”
water molecules were positioned close to the bound drug, they never interacted with the
drug directly, only assisted in positioning the nearby residues. In ANT_HOLO, only a few of
the trapped water molecules were located near one of the kanamycin A molecules and they
interacted with different amino acids in each simulation. Therefore, perhaps these water
molecules were not significant for the complex formation. In the AAC_HOLO simulation,
we found only one such stable water molecule, close to residues Tyr 93, Trp 103, Thr 151,
Asp 152, Ile 114, and Asp 115 (Figure 4.39A). Interestingly, this was the same water molecule
in each of the three independent runs of this simulation. In the last complex simulation,
APH_HOLO, the trapped water molecules gathered close to the magnesium ions and helped
to stabilize the nearby amino acids, Asp 208 and Asp 190 (Figure 4.39B).
Although the strongest receptor:ligand interactions are those formed directly, water
molecules are often found in binding sites of experimentally resolved complex structures.
It has been shown that these water molecules buried deeply inside active sites of enzymes
have different features from water in bulk.224 Moreover, displacing a water molecule that
bridges the receptor:ligand interaction and substituting it for a covalently bound moiety can
lower the efficacy of binding.225 Other theoretical studies highlight the importance of tak-
ing into account water-bridged interactions when analyzing structure activity relationships
during a drug design process.226 As described above, our simulations reveal potentially
important sites for water-mediated interactions previously not explored.
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(A) APH_HOLO (B) AAC_HOLO
(C) ANT_HOLO
Figure 4.38: Water-mediated hydrogen bonds near kanamycin A in AME binding clefts. The blue
surfaces represent the areas of high water density (> 0:06, > 0:07 and > 0:085 water molecules
per Å3 for AAC_HOLO, ANT_HOLO, and APH_HOLO, respectively). In panels (A–B) the dense
areas are superimposed on a snapshot from the simulations, which confirms that the shown water-
bridged hydrogen bonds lasted for almost entire simulation. In panel (C) an average structure of
ANT_HOLO is shown. The sticks are colored according to the atom type: H atoms are white, O —
red, N — blue, C atoms of the antibiotic — green, other C atoms — cyan. The magnesium ion is
shown as a pink sphere.
(A) AAC_HOLO (B) APH_HOLO
Figure 4.39: The most stable water molecules in the AME:KAN complexes. Snapshots from the
simulations showing the interactions between the enzyme, kanamycin A and the “trapped” water
molecules (in the case of APH_HOLO, -factors for the water molecules for all three simulations
were6 30 Å2; in the case of AAC_HOLO, mean -factor for all three simulations was 13:52:3 Å2).
The water molecules are shown as spheres, and the interacting residues — as sticks colored according
to atom type: H atoms in white, O — red, N — blue, P — orange, C atoms of the antibiotic — green,
C atoms of ATP or ACO — light blue, other C atoms — cyan. The magnesium ions are shown as
pink spheres.
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4.3.7 Energetical analysis of kanamcyin A complexes
Enzymes mimic predominantly electrostatic interactions
A per-residue decomposition of the MMGBSA binding free energies was performed to
show the most favorable interactions formed with kanamycin A in different receptors. In
Figure 4.40 the five amino acids contributing the most to binding with kanamycin A are il-
lustrated and their energetic contribution is decomposed into parts that come from the van
der Waals (vdW), electrostatic (e-s) or non-polar term (related to the solvent accessible sur-
face, sas). In the rRNA binding site, the phosphate backbone created the most favorable
interactions (phosphate groups of G1494 and A1493). However, the enzymes utilized the
side chains of amino acids to mimic these interactions. As mentioned earlier, different amino
acids were involved in hydrogen bonding with kanamycin A, but the energetic analysis
shows that the most important were Asp or Glu. In the A-site every aminoglycoside has its
ring I stacked on top of G1491, which suggests that it is an important interaction. However,
the energetical analysis shows that this base did not give a significant contribution to bind-
ing (the van der Waals component of the energy was relatively strong, but the electrostatic
part did not favor binding; data not shown). This can possibly provide an explanation for
the majority of AMEs not reproducing the stacking inside their binding cleft. It could be
more efficient to focus on mimicking the electrostatic interactions. Moreover, amino acids
forming stacking have large hydrophobic side chains, which cannot change their conforma-
tion as easily as e.g., Asp or Glu, and this flexibility is necessary if an enzyme is to adapt to
different shapes and sizes of aminoglycosides.
The energetical analysis showed that the Glu residues from the aminoglycoside binding
loop in APH (residues from around Asp 150 to Asp 162) were the most important for kana-
mycin A binding (Figure 4.40). In contrast, the amino acids forming the mobile loop in AAC
(from Glu 47 to Arg 55) did not give such a strong contribution to the binding free energy —
in the five most significant amino acids, only Trp 49 is present, contributing strongly through
the stacking. This suggests that the role of this AAC fragment may be to block a premature
release of the drug from the binding pocket, while in APH, the loop specifically recognizes
the antibiotic. Importantly, the relative orientation of kanamycin A and the surface of the
binding pocket in APH is rotated by 180 when compared with the other two enzymes or the
A-site, as can be seen in the bottom panels in Figure 4.40. This means that the most energet-
ically favorable interactions were formed predominantly with rings II and III in the case of
the APH_HOLO simulations, and with rings I and II in the case of the other receptors. Nev-
ertheless, rings I and II were forming strong hydrogen bonds with APH, as shown earlier.
Another uniqe feature of APH_HOLO is the high electrostatic contribution to binding of the
C-terminal residues Asp 261, Glu 262 and Phe 264. These residues were forming hydrogen
bonds with kanamycin A using both, their side chains and backbone, as shown by the de-
composition of the energy in Figure 4.40 and by the hydrogen bond analysis in Table 4.9.
These interactions are most likely the same in complexes with different aminoglycosides,
because these amino acids are highly conserved within the APH(30) subfamily and impor-
tant for the activity of these enzymes.222 The energetical analysis of the ANT:KAN complex
is in agreement with recent mutational studies of ANT(40),220 which showed that the ANT
double mutant E145Q/E76Q lacks enzyme activity, while the single mutants (E145Q and
E76Q) had no substantial change in the reaction constants for modification of kanamycin A.
Our energy decomposition demonstrated that both of these amino acids contribute favor-
ably to the binding, and thus the lack of only one of these contributions would not have a
big impact on the complex stability.
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Figure 4.40: Per-residue decomposition of the MMGBSA free binding energy for the studied AME
complexes (all energy values are given in kcal/mol).
(three top panels) “Efficiency” was calculated as the ratio of the MMGBSA energy difference to the
number of heavy atoms in the residue and only the five most important energetically residues are
shown in order of decreasing significance. The MMGBSA energy difference ( energy) between the
calculated energy of a residue in the APO and HOLO simulations, is decomposed into: vdW = van
der Waals interactions, e-s = electrostatic interactions, sas = non-polar contribution, related to the
solvent accessible surface area; abbreviations in brackets: bck = backbone, side = side chain.
(bottom panels) The residues that favor kanamycin A binding (black sticks) are marked green and
labeled in the order of importance; the asterisks (*) mark ring I — notice that the orientation of
kanamycin A in the APH binding cleft is opposite to the one in the A-site.
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4.3.8 Summary
The results from our simulations of AME representatives highlighted the similarities
and differences between the aminoglycoside binding sites in these enzymes and in the rRNA
A-site. The three enzymes were found to have different flexibility patterns, which we hy-
pothesize correlates with different ways of achieving promiscuity towards aminoglycosides.
The APH representative was the most flexible in the APO state, and it only stabilized upon
complex formation with the drug. The different conformations sampled by this enzyme
show that the binding of the drug occurs through an induced fit mechanism. The AAC
enzyme was also flexible, mostly due to high mobility of the loops located over the amino-
glycoside binding site. This finding is similar to what we observed in the APH simulations;
however, in contrast to APH, the loop in AAC did not form energetically important inter-
actions with the drug. We postulate that AAC is able to bind different aminoglycosides
because it possesses aromatic residues in the binding site that form stacking interactions
with the aminoglycoside rings. The third enzyme, ANT, was the least flexible, but its bind-
ing site is comprised of many hydrogen bond donors that create direct and water-mediated
interactions with aminoglycosides.
Our analysis demonstrated how similar the interactions formed by the enzymes and
RNA with kanamycin A were. Although each enzyme has a slightly different electrostatic
potential inside its binding site, the hydrogen bonds and even stacking were literally copied
from the A-site:KAN complex. Energetic analysis confirmed that the most important in-
teractions formed with kanamycin A were of the same nature, with Asp or Glu residues
mimicking the phosphate groups of RNA. In addition, we showed that water molecules are
involved in stabilizing AME:KAN complexes, through a complicated network of hydrogen
bonds with the amino acids inside the aminoglycoside binding sites.

Chapter 5
Conclusions and outlook
The research presented here focused on clarifying the atomic details of two mechanisms
of bacterial resistance against aminoglycoside antibiotics: (i) mutations in the region of the
primary aminoglycoside binding site, the A-site in 16S rRNA; and (ii) chemical modification
of aminoglycosides by AMEs. The computational biophysical tools enabled us to study the
static and dynamic features of the biomolecules that bind aminoglycosides inside bacterial
cell. Additionally, we proposed a new tool that analyzes the conformations of a molecule
and defines its division into dynamic domains. This approach facilitates the description of
dynamic changes that can be sampled through NMR experiments or computer simulations.
In the first part of the research different mutations in the A-site were examined. We
showed that these substitutions have different effects on the physicochemical features of
this RNA fragment. Figure 5.1 illustrates this a concise manner. We have found that some
mutations affected the shape of the aminoglycoside binding site, while some changed the
charge distribution. Our results are in accord with experimental findings and suggested
which aminoglycoside substituents should be modified so that aminoglycosides would also
bind to the mutated A-site to overcome mutation-related bacterial resistance.
Concerning the second bacterial resistance method, we have found both, similar and
dissimilar features of the aminoglycoside binding sites in representative AMEs and RNA.
We noted that the three AME representatives employ different techniques to effectively bind
aminoglycosides that vary in shape and size. On the other hand, it appears that AMEs,
built of amino acids, mimic the interaction sites from RNA, which is made of nucleic bases
(illustrated in Figure 5.2). The energetic analysis showed that these interactions were copied
efficiently.
The main tool used here, MD simulation, enables detailed analysis of atomic interac-
tions; however, due to its approximations, it has many drawbacks. The feature that most
influences the results is the limited sampling of one MD simulation, which is restricted to
one or a few local energy minima. Therefore, we tried to increase the sampling by either sim-
ulating two copies of a system or performing multiple simulation runs. However, even this
cannot guarantee observation of all conformations that are important for a given problem.
Next, the force field is only a molecular-mechanics based approximation of a real description
of interatomic interactions, hence the potential energies of a molecule and the free binding
energies give just a crude estimation of the real values and only their relative values can be
taken into account. In addition, the time scales of conformational changes do not mirror the
experimental values, and therefore, the observations have only statistical meaning. More-
over, even though the force fields have significantly improved since their first usage in the
1970s, they are still far from being perfect. This is especially the case for RNA because the
RNA-specific force fields were formulated only some time after the force fields for proteins.
Nevertheless, when used with caution, MD simulation is a very powerful tool.
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Figure 5.1: Graphical representation of key findings concerning mutations in the rRNA A-site. The
mutations studied here led to different changes in the physicochemical features of the binding site:
the biggest changes were caused by the double mutation U1406C/U1495A, including disruption of
the hydrogen bonds formed with its complex with paromomycin; mutations in position 1491 altered
the shape of the binding cleft; all mutations affected the mobility of A1492 and A1493 (shown here
are exemplary values presenting the percentage of the simulation time when each adenine was in the
flipped-in state).
Figure 5.2: Graphical representation of key findings concerning AME-mediated aminoglycoside
modifications. Kanamycin A is recognized and bound by different biomolecules: (from top right, anti-
clockwise) the rRNA A-site, the very flexible APH(30,500)-IIIa, the dimeric and relatively rigid ANT(40),
and the flexible AAC(60)-Ib. Despite the intrinsic differences in the entities that compose these recep-
tors (nucleotides in RNA and amino acids in AMEs), these various biomolecules create very similar
environment inside the aminoglycoside binding sites, utilizing mainly electrostatic interactions to
effectively bind aminoglycosides.
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The results presented here may lead to some aminoglycoside modifications that would
enable them to bind to the rRNA A-site but hinder binding to AMEs. Then, a proper
structure-based drug design approach could be employed to yield several compounds that
could be tested in the laboratory. Apart from application to antibiotic design, the AME su-
perfamily presents an elegant system for studying the relation between structure and func-
tion of a protein. The enzymes from the different families, AACs, ANTs, and APHs, differ
in structure, but still perform the same function. Moreover, the AAC(60)-Ib studied here has
a unique sequence but similar structure to other AAC(60) enzymes. The modeling meth-
ods and comparative analysis of more AME:drug complexes could give insight into specific
features that must be present in order for different structures to perform a similar function.
In addition, aminoglycosides and their receptors, especially RNA, are a strong test system
for improving existing docking procedures. Not only must the drugs be adjusted to the
receptor, but both the RNA and AMEs have different conformations when bound to dif-
ferent ligands, which was also shown here. Therefore, development of the flexible docking
procedures is needed. Moreover, none of the well-established docking programs account for
water molecules in a binding site, which can significantly increase the stability of a complex.
Finally, we presented a new algorithm for analyzing conformational changes in biomol-
ecules, GeoStaS. We have shown that our new approach performs better than a commonly
used tool, DCCM, to analyze MD simulations. Our algorithm and software correctly rec-
ognizes correlated motions and can facilitate the analysis of large trajectories through vi-
sualization of the identified dynamic domains. However, the implementation still needs
some improvement. We plan to test another method of clustering AMSM, and improve
the process of choosing the optimal division into dynamic domains. Additionally, to com-
plete the description of the conformational diversity of a molecule, we would like to find
a representative set of conformations, i.e., cluster a trajectory. These transitions can then
be presented as relations between the clusters, and the relative orientations of the dynamic
domains can efficiently describe the clusters. Such an approach would enable researchers to
focus on important details of the molecular interactions rather than on the time-consuming
post-processing of a trajectory.
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